4-toluenesulfonamide profile

4-toluenesulfonamide: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

toluene-4-sulfonamide : A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6269
CHEMBL ID	574
CHEBI ID	34435
SCHEMBL ID	7370
MeSH ID	M0084735

Synonym
BIDD:ER0609
BB 0258885
4-methyl-benzenesulfonamide
NCI60_042220
p-tosylamide
nsc-9908
nsc9908
tolylsulfonamide
70-55-3
toluene-4-sulfonamide
4-methylbenzenesulfonamide
wln: zswr d1
p-toluenesulfamide
p-tolylsulfonamide
benzenesulfonamide, 4-methyl-
tosylamide
4-toluenesulfonamide
p-toluenesulfonamide
toluene-p-sulfonamide
p-methylbenzenesulfonamide
p-toluenesulfonylamide
NCGC00091435-01
4-methylbenzene-1-sulfonamide
chembl574 ,
aromatic/heteroaromatic sulfonamide 4
bdbm10859
p-toluenesulfonamide, reagentplus(r), >=99%
p-toluenesulfonamide, reagent grade, 98%
NCGC00091435-02
CHEBI:34435 ,
ai3-19503
hsdb 5203
4-toluenesulfanamide
para-toluenesulfonamide
4-toluenesulfonic acid, amide
einecs 200-741-1
toluene-p-sulphonamide
brn 0472689
toluene-4-sulphonamide
nsc 9908
MLS001065595
smr000568494
STK416410
AKOS000149655
paratoulene sulfonamide
toluenesulfonamide, p-
T0281
pasam
NCGC00091435-03
HMS3039B12
dtxsid8029105 ,
tox21_303506
dtxcid109105
NCGC00257435-01
cas-70-55-3
tox21_201594
NCGC00259143-01
unii-i8266ri90m
i8266ri90m ,
ec 200-741-1
4-11-00-00376 (beilstein handbook reference)
BP-12584
FT-0646496
FS-3585
AE-562/40173366
F0722-8812
p-toluenesulfonamide [usp-rs]
tolbutamide impurity a [ep impurity]
p-toluenesulfonamide [hsdb]
SCHEMBL7370
4-tolylsulphonamide
p-toluene sulfonamide
p-toluenesulfonic amide
p-methyl-benzene sulfonamide
tosylamine
p-toluensulfonamide
p-toluene-sulfonamide
4-methylphenyl sulfonamide
4-methylphenylsulphonylamine
p-toluenesulphonamide
4-toluenesulphonamide
4-methyl benzenesulfonamide
para-toluen sulphonamide
para-toluene sulphonamide
p-toluene sulphonamide
4-methylphenylsulphonamide
W-104550
1219795-34-2
W-109664
mfcd00011692
4j8 ,
4-tolyl-d4-sulfonamide
p-toluenesulfonamide, united states pharmacopeia (usp) reference standard
Z45415564
p-toluenesulfonamide, vetec(tm) reagent grade, 98%
4-methylbenzenesulphonamide
CS-0012133
p-toluenesulfonamide,(s)
Q23013959
12552-95-3
AMY37180
n-p-tolylsulfonylamine
4-tolylsulfonamide
EN300-15721
HY-79602

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
AR protein	Homo sapiens (human)	Potency	51.2060	0.0002	21.2231	8,912.5098	AID1259243; AID1259381
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	16.1810	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	21.7440	0.0002	29.3054	16,493.5996	AID743069
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	8.6554	0.0010	24.5048	61.6448	AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	27.3707	0.0237	23.2282	63.5986	AID743223
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	25.1189	0.0007	23.0674	1,258.9301	AID651777
thyrotropin-releasing hormone receptor	Homo sapiens (human)	Potency	43.3852	0.1549	17.8702	43.6557	AID1346891
tumor necrosis factor	Homo sapiens (human)	Potency	3.3491	0.3758	23.4928	42.1632	AID651757
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	68.5896	0.0006	27.2152	1,122.0200	AID651741
geminin	Homo sapiens (human)	Potency	0.0847	0.0046	11.3741	33.4983	AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase	Astrosclera willeyana	Ki	0.6750	0.0320	1.5172	9.6000	AID644379
Carbonic anhydrase	Sulfurihydrogenibium sp. YO3AOP1	Ki	0.8480	0.0045	0.1624	0.8760	AID1268964
Carbonic anhydrase	Stylophora pistillata	Ki	0.6140	0.0000	0.6867	10.0000	AID436565; AID552130
Carbonic anhydrase	Stylophora pistillata	Ki	0.5160	0.0000	0.5071	5.7100	AID552131
Carbonic anhydrase	Helicobacter pylori 26695	Ki	0.4615	0.0200	0.5486	4.3600	AID261581; AID263638
Carbonic anhydrase 12	Homo sapiens (human)	Ki	0.0018	0.0002	1.1043	9.9000	AID238316
Carbonic anhydrase 1	Homo sapiens (human)	IC50 (µMol)	13.9350	0.0058	2.1410	7.9000	AID1803142
Carbonic anhydrase 1	Homo sapiens (human)	Ki	69.0036	0.0000	1.3726	10.0000	AID1142833; AID1188134; AID1190063; AID1194024; AID1195369; AID1254399; AID1268962; AID1275913; AID1287517; AID1291357; AID1434427; AID1453412; AID1628036; AID1796552; AID1798769; AID1803133; AID238247; AID238276; AID261579; AID263636; AID275807; AID349605; AID367820; AID369271; AID414955; AID427125; AID436563; AID552127; AID577526; AID612725; AID644380; AID725955
Carbonic anhydrase 2	Homo sapiens (human)	IC50 (µMol)	10.5963	0.0002	1.1060	8.3000	AID1803142; AID241604
Carbonic anhydrase 2	Homo sapiens (human)	Ki	5.6053	0.0000	0.7236	9.9200	AID1061069; AID1142834; AID1188135; AID1190064; AID1194025; AID1195370; AID1240217; AID1254400; AID1268963; AID1275912; AID1278409; AID1287518; AID1291358; AID1434428; AID1453413; AID1628037; AID1796552; AID1796582; AID1798769; AID1803133; AID238255; AID238300; AID256963; AID261580; AID263637; AID275808; AID349606; AID367821; AID369272; AID414956; AID427124; AID436564; AID437749; AID552128; AID577527; AID612726; AID644381; AID669115; AID725956; AID729565
Carbonic anhydrase 2	Bos taurus (cattle)	Ki	1.6467	0.0025	1.1325	7.5858	AID550080
Carbonic anhydrase 3	Homo sapiens (human)	Ki	7.9000	0.0002	2.0102	10.0000	AID301578
Carbonic anhydrase 6	Homo sapiens (human)	IC50 (µMol)	13.9350	0.0200	1.3317	5.7900	AID1803142
Carbonic anhydrase 6	Homo sapiens (human)	Ki	20.2674	0.0001	1.4710	9.9200	AID1798769; AID1803133; AID275806; AID369273; AID552129
Delta-type opioid receptor	Mus musculus (house mouse)	Ki	39.4100	0.0000	0.5393	9.4000	AID1188134; AID1188135
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	0.3200	0.0000	0.6068	9.2330	AID1188135
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	78.5000	0.0000	0.3845	8.6000	AID1188134
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	IC50 (µMol)	4.7000	0.0200	3.1081	9.4000	AID241574
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Ki	3.0375	0.0000	1.2725	9.9000	AID1796582; AID256964
Carbonic anhydrase 7	Homo sapiens (human)	Ki	0.0880	0.0002	1.3737	9.9000	AID238256
Carbonic anhydrase	Saccharomyces cerevisiae S288C	Ki	16.1000	0.0820	0.5609	8.7000	AID367822
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.3200	0.0000	0.2786	9.0000	AID1188135
Beta-carbonic anhydrase 1	Mycobacterium tuberculosis H37Rv	Ki	4.9200	0.0048	3.3841	9.8400	AID1798985; AID349607
Carbonic anhydrase 2	Mycobacterium tuberculosis H37Rv	Ki	38.9000	0.0090	2.2096	9.8400	AID437750
Carbonic anhydrase 9	Homo sapiens (human)	Ki	2.6230	0.0001	0.7874	9.9000	AID1798769; AID275809; AID369274
Carbonic anhydrase, alpha family	Hydrogenovibrio crunogenus XCL-2	Ki	0.2440	0.0025	0.3234	1.1000	AID1268965
Carbonic anhydrase	Cryptococcus neoformans var. grubii	Ki	1.1500	0.0100	0.7364	8.3470	AID669116
Carbonic anhydrase	Candida albicans SC5314	Ki	1.1905	0.0105	1.4444	8.3470	AID1799266; AID427122; AID669117
Carbonic anhydrase	Anopheles gambiae (African malaria mosquito)	Ki	12.4000	0.0098	0.5117	4.3600	AID1195371
Delta carbonic anhydrase	Conticribra weissflogii	Ki	0.4240	0.0496	0.9978	9.2000	AID1061066
Carbonic anhydrase	Nakaseomyces glabratus CBS 138	Ki	0.8460	0.0070	1.2174	9.1700	AID744415
Carbonic anhydrase 15	Mus musculus (house mouse)	Ki	5.8540	0.0009	1.8846	10.0000	AID1798769; AID369275
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Ki	2.4700	0.0000	1.3412	9.9700	AID1796582; AID256965
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase 2	Homo sapiens (human)	Kd	156.2575	0.0000	0.4157	5.5500	AID1307761; AID1307762; AID1468997; AID1469000
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase	Brucella suis 1330	Kinact	1.5800	0.0170	0.8628	5.8700	AID459696
Carbonic anhydrase 1	Homo sapiens (human)	Kinact	78.5000	0.0100	0.9387	8.6000	AID299242
Carbonic anhydrase 2	Homo sapiens (human)	Kinact	0.3200	0.0030	0.7946	10.0000	AID299243
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Bos taurus (cattle)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Bos taurus (cattle)
regulation of intracellular pH	Carbonic anhydrase 2	Bos taurus (cattle)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Bos taurus (cattle)
response to bacterium	Carbonic anhydrase 3	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 3	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter taste	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Bos taurus (cattle)
cyanamide hydratase activity	Carbonic anhydrase 2	Bos taurus (cattle)
carbonate dehydratase activity	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 3	Homo sapiens (human)
nickel cation binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Bos taurus (cattle)
plasma membrane	Carbonic anhydrase 2	Bos taurus (cattle)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 3	Homo sapiens (human)
extracellular region	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
cytosol	Carbonic anhydrase 6	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (216)

Assay ID	Title	Year	Journal	Article
AID1796552	CA Inhibition Assay from Article 10.1021/jm0512600: \\Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.\\	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1803142	Esterase Activity Assay from Article 10.3109/14756366.2011.617745: \\Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.\\	2012	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6	Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.
AID1798985	CA Inhibition Assay from Article 10.1021/jm9000488: \\Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.\\	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1798769	CA Inhibition Assay from Article 10.1021/jm801267c: \\Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.\\	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1803133	CA Activity Assay from Article 10.3109/14756366.2011.614607: \\Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.\\	2012	Journal of enzyme inhibition and medicinal chemistry, Oct, Volume: 27, Issue:5	Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.
AID1799266	CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: \\Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.\\	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1796582	CA Inhibition Assay from Article 10.1021/jm050483n: \\Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.\\	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1798982	CA Inhibition Assay from Article 10.1021/jm9003126: \\Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.\\	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID744415	Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID261580	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID669120	Antimicrobial activity against Malassezia furfur CBS 9569 after 7 days	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1142837	Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1434430	Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID552128	Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID239935	Inhibition constant against carbonic anhydrase	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID1453410	Inhibition of Francisella tularensis beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID1194026	Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1194024	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID1190065	Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID263639	Selectivity for Helicobacter pylori recombinant CA over human recombinant CA2	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1307760	Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as dissociation kinetic constant by SPR method	2016	Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9	Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID369271	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1287519	Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID1123578	Inhibition of carbonic anhydrase (unknown origin) at 15 degC	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Correlation of carbonic anhydrase inhibitory activities of benzenesulfonamides with the data obtained by use of nitrogen-14 nuclear quadrupole resonance.
AID1061069	Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID612731	Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID566702	Inhibition of human recombinant MMP1 at 1 mM after 30 mins	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1190064	Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID261582	Selectivity ratio for human carbonic anhydrase 2 over Helicobacter pylori carbonic anhydrase	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID566706	Inhibition of human recombinant MMP9 at 1 mM after 30 mins	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1268964	Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1123579	Inhibition of carbonic anhydrase (unknown origin) relative to sulfanilamide	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Correlation of carbonic anhydrase inhibitory activities of benzenesulfonamides with the data obtained by use of nitrogen-14 nuclear quadrupole resonance.
AID1061169	Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID1240216	Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID243139	Binding constant against human Carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	QSAR studies on benzene sulfonamide carbonic anhydrase inhibitors: need of hydrophobic parameter for topological modeling of binding constants of sulfonamides to human CA-II.
AID1291358	Inhibition of recombinant human carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID261579	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1453412	Inhibition of human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID669123	Antimicrobial activity against Malassezia globosa CBS 7966 after 7 days	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1307759	Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as association kinetic constant by SPR method	2016	Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9	Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID1628038	Inhibition of recombinant Plasmodium falciparum eta-carbonic anhydrase (181 to 538 residues) expressed in Escherichia coli artic express (DE3) preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID1188137	Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1240214	Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID552129	Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID50176	Binding affinity against human carbonic anhydrase (hCA).	1999	Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25	Simple linear QSAR models based on quantum similarity measures.
AID263636	Inhibition of human recombinant CA1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID566705	Inhibition of human recombinant MMP8 at 1 mM after 30 mins	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1188136	Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1287517	Inhibition of human carbonic anhydrase 1 incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID1278413	Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1434427	Inhibition of recombinant human carbonic anhydrase 1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID566700	Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID669121	Antimicrobial activity against Malassezia dermatis CBS 9145 after 7 days	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID244146	Selectivity for Carbonic anhydrase II to that of Carbonic anhydrase V	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.
AID1307761	Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as dissociation constant by SPR method	2016	Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9	Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID1123580	Inhibition of carbonic anhydrase (unknown origin) at 0.2 degC	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	Correlation of carbonic anhydrase inhibitory activities of benzenesulfonamides with the data obtained by use of nitrogen-14 nuclear quadrupole resonance.
AID263638	Inhibition of Helicobacter pylori recombinant CA	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID369275	Inhibition of mouse recombinant carbonic anhydrase 15 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1134599	CHCl3-water partition coefficient, log P of the compound	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID778725	Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.
AID1142836	Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1142834	Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1254400	Inhibition of cytosolic carbonic anhydrase 2 esterase activity isolated from human serum using 4-nitrophenylacetate as substrate measured over 3 mins by spectrophotometric analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives.
AID1268965	Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1188135	Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID1278410	Inhibition of Porphyromonas gingivalis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1268963	Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID1291355	Inhibition of recombinant Vibrio cholerae beta-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID427123	Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID243010	Selectivity ratio for human carbonic anhydrases II and XII	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1061170	Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID244692	Diuretic activity was determined	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID50340	Binding constant of ligand was determined by Affinity capillary electrophoresis (ACE) using bovine carbonic anhydrase-B	1993	Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1	Use of affinity capillary electrophoresis to determine kinetic and equilibrium constants for binding of arylsulfonamides to bovine carbonic anhydrase.
AID275808	Inhibition of human recombinant cytosolic isozyme CA II by stopped-flow CO2 hydrase method	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID299250	Inhibition of Helicobacter pylori beta carbonic anhydrase by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID238255	Ki value against human carbonic anhydrase II	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID1194027	Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID644380	Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1275910	Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID237613	Diuretic activity was determined	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID1142838	Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID436564	Inhibition of human recombinant CA2 by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID550080	Binding affinity to bovine carbonic anhydrase 2	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Correlation analyses on binding affinity of substituted benzenesulfonamides with carbonic anhydrase using ab initio MO calculations on their complex structures (II).
AID436563	Inhibition of human recombinant CA1 by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID644381	Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID275806	Inhibition of full length human recombinant CA VI	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID299243	Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID669115	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID644379	Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID1194025	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID711212	Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1275911	Inhibition of Vibrio cholerae alpha-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1278412	Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID243144	Partition coefficient (logP)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	QSAR studies on benzene sulfonamide carbonic anhydrase inhibitors: need of hydrophobic parameter for topological modeling of binding constants of sulfonamides to human CA-II.
AID1190063	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID369273	Inhibition of human full length recombinant carbonic anhydrase 6 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1434429	Inhibition of Burkholderia pseudomallei Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1291357	Inhibition of recombinant human carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID552127	Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID239922	Inhibitory activity against carbonic anhydrase	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID1134600	Octanol-water partition coefficient, log P of the compound	1977	Journal of medicinal chemistry, Aug, Volume: 20, Issue:8	Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID238300	Ki value against human carbonic anhydrase II (hCA II)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID566701	Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1453411	Inhibition of Burkholderia pseudomallei beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID669119	Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1195371	Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID367821	Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID238276	Ki value against human carbonic anhydrase I (hCA I)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1142833	Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1278411	Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1254399	Inhibition of cytosolic carbonic anhydrase 1 esterase activity isolated from human serum using 4-nitrophenylacetate as substrate measured over 3 mins by spectrophotometric analysis	2015	Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23	Carbonic anhydrase inhibitors: Design, synthesis, kinetic, docking and molecular dynamics analysis of novel glycine and phenylalanine sulfonamide derivatives.
AID437749	Inhibition of human recombinant CA2 by stopped-flow hydration assay	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID369272	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID612732	Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID566707	Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID299249	Inhibition of Helicobacter pylori alpha carbonic anhydrase by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID241604	Inhibitory concentration against human cystolic isozyme II of Carbonic anhydrase	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.
AID612726	Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID552131	Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1061066	Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID1195370	Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID238567	Ki value against murine carbonic anhydrase XIII was determined; (not tested)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID329898	Binding affinity to carbonic anhydrase	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Ligand binding efficiency: trends, physical basis, and implications.
AID414956	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID241574	Inhibitory concentration against human cystolic isozyme V of Carbonic anhydrase	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.
AID1453413	Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID725955	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID367820	Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID1275912	Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID566703	Inhibition of human recombinant MMP2 at 1 mM after 30 mins	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1195369	Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID427122	Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1278409	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay	2016	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID256963	Inhibitory activity against human recombinant cytosolic CA2	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID459696	Inhibition of Brucella suis CA1 expressed in Escherichia coli BL21(DE3) by stopped-flow CO2-hydration assay	2010	Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5	Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.
AID729565	Inhibition of human esterase activity of carbonic anhydrase 2 using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID577530	Inhibition of Brucella suis carbonic anhydrase II by spectrophotometry at pH 8.3	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID237422	Partition coefficient (logP)	2004	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22	Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID369274	Inhibition of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydrase assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID566704	Inhibition of human recombinant MMP3 at 1 mM after 30 mins	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID238256	Ki value against human carbonic anhydrase VII	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID729567	Inhibition of sheep kidney esterase activity of carbonic anhydrase using 4-nitrophenylacetate as substrate after 3 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6	Purification and characterization of carbonic anhydrase from sheep kidney and effects of sulfonamides on enzyme activity.
AID1468998	Binding affinity to human full length His-tagged CA2 (1 to 260 residues) expressed in Escherichia coli BL21(DE3) assessed as intrinsic association rate constant after 60 secs at pH 7 by SPR assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.
AID1434428	Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID1268962	Inhibition of recombinant human carbonic anhydrase-1 by stopped flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID367822	Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID1287520	Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID349608	Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1287518	Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID275809	Inhibition of catalytic domain of human recombinant CA IX	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID577531	Inhibition of Brucella suis carbonic anhydrase I by spectrophotometry at pH 8.3	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID612725	Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID275807	Inhibition of human recombinant cytosolic isozyme CA I by stopped-flow CO2 hydrase method	2007	Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2	Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID301578	Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
AID1291363	Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID436565	Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID50169	Inhibitory activity against bovine Carbonic anhydrase	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	The binding of benzenesulfonamides to carbonic anhydrase enzyme. A molecular mechanics study and quantitative structure-activity relationships.
AID566699	Inhibition of mushroom tyrosinase at 1 mM after 10 mins	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1061068	Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID577526	Inhibition of human carbonic anhydrase I by spectrophotometry at pH 7.5	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID1468999	Binding affinity to human full length His-tagged CA2 (1 to 260 residues) expressed in Escherichia coli BL21(DE3) assessed as intrinsic dissociation rate constant at pH 7 by SPR assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.
AID1188138	Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID256964	Inhibitory activity against human recombinant mitochondrial isozyme CA VA	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1275913	Inhibition of human Carbonic anhydrase1 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5	Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1469000	Binding affinity to human full length His-tagged CA2 (1 to 260 residues) expressed in Escherichia coli BL21(DE3) assessed as intrinsic thermodynamic equilibrium constant at pH 7 by SPR assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.
AID427124	Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID669117	Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID261581	Inhibition of Helicobacter pylori recombinant carbonic anhydrase by stopped-flow CO2 hydrase assay	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID552130	Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1468996	Binding affinity to human full length His-tagged CA2 (1 to 260 residues) expressed in Escherichia coli BL21(DE3) assessed as association rate constant after 60 secs at pH 7 by SPR assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.
AID427125	Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID256965	Inhibitory activity against human recombinant mitochondrial isozyme CA VB	2005	Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24	Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1188134	Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID349607	Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1893771	Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis	2022	ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9	2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID437750	Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID238316	Ki value against human carbonic anhydrase XII (hCA XII)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID19262	Aqueous solubility	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Prediction of drug solubility from Monte Carlo simulations.
AID263637	Inhibition of human recombinant CA2	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID1628037	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID1468989	Binding affinity to human full length His-tagged CA2 (1 to 260 residues) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant at pH 7 by SPR assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.
AID726232	Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1240215	Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1291361	Inhibition of recombinant Vibrio cholerae alpha-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay	2016	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8	Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID1240217	Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1136505	Inhibition of carbonic anhydrase (unknown origin)	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	A manual method for applying the Hansch approach to drug design.
AID349605	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID414961	Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1307762	Binding affinity to GST-fused human carbonic anhydrase-2 expressed in Escherichia coli BL21 codon plus cells assessed as steady state dissociation constant by SPR method	2016	Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9	Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human Carbonic Anhydrase by Computational and Experimental Studies.
AID1061067	Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID577527	Inhibition of human carbonic anhydrase II by spectrophotometry at pH 7.5	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID238247	Ki value against human carbonic anhydrase I	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID1204106	Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
AID1468997	Binding affinity to human full length His-tagged CA2 (1 to 260 residues) expressed in Escherichia coli BL21(DE3) assessed as thermodynamic equilibrium constant at pH 7 by SPR assay	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Introduction of Intrinsic Kinetics of Protein-Ligand Interactions and Their Implications for Drug Design.
AID1194028	Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay	2015	Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8	Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID237031	Partition coefficient (logP)	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID1628036	Inhibition of full length human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stop flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17	Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID414955	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID349606	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID669122	Antimicrobial activity against Malassezia pachydermatis CBS 6536 after 7 days	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID725956	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID669116	Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID299242	Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (8.33)	18.7374
1990's	6 (5.56)	18.2507
2000's	37 (34.26)	29.6817
2010's	51 (47.22)	24.3611
2020's	5 (4.63)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (1.77%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (0.88%)	4.05%
Observational	0 (0.00%)	0.25%
Other	110 (97.35%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Trials	Classes	Roles
anisindione	[no description available]	medium	1	0	aromatic ketone; beta-diketone	anticoagulant; vitamin K antagonist
benzamide	[no description available]	medium	3	0	benzamides
amphetamine	[no description available]	medium	1	0	primary amine
p-chloroamphetamine	[no description available]	medium	1	0
phenindione	[no description available]	medium	1	0	aromatic ketone; beta-diketone	anticoagulant
sulfabenzamide	[no description available]	medium	1	0	benzenes; sulfonamide antibiotic; sulfonamide	antibacterial drug; antimicrobial drug
benzenesulfonamide	[no description available]	medium	16	0	sulfonamide
4-methoxyamphetamine	[no description available]	medium	1	0
4-chlorobenzenesulfonamide	[no description available]	medium	7	0	sulfonamide
clorindione	[no description available]	medium	1	0	cyclic ketone; indanones
4-Methoxybenzamide	[no description available]	medium	1	0	benzamides
3,4-Dichlorobenzenesulfonamide	[no description available]	medium	5	0	sulfonamide
9-phenylguanine	[no description available]	medium	1	0
sulfanilamide	[no description available]	medium	53	0	substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; drug allergen; EC 4.2.1.1 (carbonic anhydrase) inhibitor
2-toluenesulfonamide	[no description available]	medium	9	0
4-hydroxybenzaldehyde	[no description available]	medium	1	0	hydroxybenzaldehyde	EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor; mouse metabolite; plant metabolite
ethylene glycol	[no description available]	medium	1	0	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
acetic acid	[no description available]	medium	1	0	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
acetamide	[no description available]	medium	2	0	acetamides; carboximidic acid; monocarboxylic acid amide; N-acylammonia
acetone	[no description available]	medium	1	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
benzaldehyde	[no description available]	medium	2	0	benzaldehydes	EC 3.1.1.3 (triacylglycerol lipase) inhibitor; EC 3.5.5.1 (nitrilase) inhibitor; flavouring agent; fragrance; odorant receptor agonist; plant metabolite
benzene	[no description available]	medium	2	0	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent
benzoic acid	[no description available]	medium	2	0	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
benzyl alcohol	[no description available]	medium	1	0	benzyl alcohols	antioxidant; fragrance; metabolite; solvent
2,3-butylene glycol	[no description available]	medium	1	0	butanediol; glycol; secondary alcohol
1-butanol	[no description available]	medium	1	0	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
butyric acid	[no description available]	medium	1	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
3-cresol	[no description available]	medium	1	0	cresol	human xenobiotic metabolite
acetanilide	[no description available]	medium	2	0	acetamides; anilide	analgesic
n,n-dimethylaniline	[no description available]	medium	1	0	dimethylaniline; tertiary amine
phenol	[no description available]	medium	2	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
phenylacetic acid	[no description available]	medium	1	0	benzenes; monocarboxylic acid; phenylacetic acids	allergen; Aspergillus metabolite; auxin; EC 6.4.1.1 (pyruvate carboxylase) inhibitor; Escherichia coli metabolite; human metabolite; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite; toxin
propylene glycol	[no description available]	medium	1	0	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
1-propanol	[no description available]	medium	2	0	propan-1-ols; short-chain primary fatty alcohol	metabolite; protic solvent
propionic acid	[no description available]	medium	1	0	saturated fatty acid; short-chain fatty acid	antifungal drug
toluene	[no description available]	medium	46	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
toluene	[no description available]	medium	46	2	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
antipyrine	[no description available]	medium	1	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
caffeine	[no description available]	medium	2	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
4-cresol	[no description available]	medium	2	0	cresol	Escherichia coli metabolite; human metabolite; uremic toxin
ether	[no description available]	medium	3	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
methenamine	[no description available]	medium	1	0	polyazaalkane; polycyclic cage; tetramine	antibacterial drug
4-chlorophenol	[no description available]	medium	1	0	monochlorophenol
propoxur	[no description available]	medium	1	0	aromatic ether; carbamate ester	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
triacetin	[no description available]	medium	1	0	triglyceride	adjuvant; antifungal drug; food additive carrier; food emulsifier; food humectant; fuel additive; plant metabolite; solvent
urethane	[no description available]	medium	1	0	carbamate ester	fungal metabolite; mutagen
aminopyrine	[no description available]	medium	1	0	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aniline	[no description available]	medium	2	0	anilines; primary arylamine
n-pentanol	[no description available]	medium	1	0	pentanol; short-chain primary fatty alcohol	human metabolite; plant metabolite
propionamide	[no description available]	medium	1	0	monocarboxylic acid amide; primary fatty amide
3-trifluoromethylphenol	[no description available]	medium	1	0	(trifluoromethyl)benzenes
acetophenone	[no description available]	medium	2	0	acetophenones	animal metabolite; photosensitizing agent; xenobiotic
nitrobenzene	[no description available]	medium	2	0	nitroarene; nitrobenzenes
ethylbenzene	[no description available]	medium	1	0	alkylbenzene
benzylamine	[no description available]	medium	2	0	aralkylamine; primary amine	allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite
benzonitrile	[no description available]	medium	2	0	benzenes; nitrile
anisole	[no description available]	medium	2	0	monomethoxybenzene	plant metabolite
phenetole	[no description available]	medium	1	0	aromatic ether
n-benzyl-n,n-dimethylamine	[no description available]	medium	1	0
4-bromophenol	[no description available]	medium	1	0	bromophenol	human urinary metabolite; human xenobiotic metabolite; marine metabolite; mouse metabolite; persistent organic pollutant; rat metabolite
3-chlorophenol	[no description available]	medium	1	0	monochlorophenol
bromobenzene	[no description available]	medium	2	0	bromoarene; bromobenzenes; volatile organic compound	hepatotoxic agent; mouse metabolite; non-polar solvent
chlorobenzene	[no description available]	medium	2	0	monochlorobenzenes	solvent
n-pentanoic acid	[no description available]	medium	1	0	short-chain fatty acid; straight-chain saturated fatty acid	plant metabolite
1,4-butanediol	[no description available]	medium	1	0	butanediol; glycol	neurotoxin; prodrug; protic solvent
1-hexanol	[no description available]	medium	1	0	hexanol; primary alcohol	alarm pheromone; antibacterial agent; fragrance; plant metabolite
1,5-pentanediol	[no description available]	medium	1	0	primary alcohol
ethyl acetate	[no description available]	medium	2	0	acetate ester; ethyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; metabolite; polar aprotic solvent; Saccharomyces cerevisiae metabolite
hexanoic acid	[no description available]	medium	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	human metabolite; plant metabolite
3-hydroxyanisole	[no description available]	medium	1	0	monomethoxybenzene; phenols
mequinol	[no description available]	medium	1	0	methoxybenzenes; phenols	metabolite
4-fluorophenol	[no description available]	medium	1	0	fluorophenol; monofluorobenzenes
3-fluorophenol	[no description available]	medium	1	0
fluorobenzenes	[no description available]	medium	2	0	monofluorobenzenes	NMR chemical shift reference compound
4-iodophenol	[no description available]	medium	1	0	iodophenol
butyramide	[no description available]	medium	1	0	butanamides; primary fatty amide
isovaleramide	[no description available]	medium	1	0
3-nitrophenol	[no description available]	medium	1	0	3-nitrophenols
succinimide	[no description available]	medium	1	0	dicarboximide; pyrrolidinone
3-bromophenol	[no description available]	medium	1	0
methyl carbamate	[no description available]	medium	1	0	carbamate ester
n,n-dimethylbenzamide	[no description available]	medium	1	0
hexamethylene glycol	[no description available]	medium	1	0	diol; primary alcohol
metolcarb	[no description available]	medium	1	0	carbamate ester	acaricide; agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor
4-hydroxyphenoxyacetic acid	[no description available]	medium	1	0	monocarboxylic acid
phenoxyacetic acid	[no description available]	medium	1	0	aromatic ether; monocarboxylic acid	allergen; Aspergillus metabolite; human xenobiotic metabolite; plant growth retardant
paraldehyde	[no description available]	medium	1	0	trioxane	sedative
4-bromobenzenesulfonamide	[no description available]	medium	5	0
phenylthiourea	[no description available]	medium	1	0	thioureas	EC 1.14.18.1 (tyrosinase) inhibitor
sulfacetamide	[no description available]	medium	1	0
2-aminobenzenesulfonamide	[no description available]	medium	26	0	benzenes; sulfonamide
2-chlorobenzenesulfonamide	[no description available]	medium	3	0
2-aminosulfonyl-benzoic acid methyl ester	[no description available]	medium	3	0	benzoate ester; methyl ester; sulfonamide	marine xenobiotic metabolite
4-aminomethylbenzoic acid	[no description available]	medium	1	0	benzoic acids
4-methylbenzylamine	[no description available]	medium	1	0
4-methoxybenzylamine	[no description available]	medium	1	0	aralkylamino compound; aromatic ether; primary amino compound
1-(1h-indol-3-ylcarbonyl)-n-(4-methoxybenzyl)formamide	[no description available]	medium	1	0
n-(indol-3-ylglyoxylyl)benzylamine	[no description available]	medium	1	0
ethylene dichloride	[no description available]	medium	1	0	chloroethanes	hepatotoxic agent; mutagen; non-polar solvent
adenine	[no description available]	medium	2	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
salicylic acid	[no description available]	medium	2	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
propionaldehyde	[no description available]	medium	1	0	alpha-CH2-containing aldehyde; propanals	Escherichia coli metabolite
dibenzofuran	[no description available]	medium	1	0	dibenzofurans; mancude organic heterotricyclic parent; polycyclic heteroarene	xenobiotic
cytosine	[no description available]	medium	1	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
alanine	[no description available]	medium	1	0	alpha-amino acid; amino acid zwitterion	fundamental metabolite
hexachlorocyclohexane	[no description available]	medium	1	0	chlorocyclohexane
indole	[no description available]	medium	1	0	indole; polycyclic heteroarene	Escherichia coli metabolite
methanol	[no description available]	medium	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
naphthalene	[no description available]	medium	1	0	naphthalenes; ortho-fused bicyclic arene	apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component
pyridine	[no description available]	medium	1	0	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
dimethyl sulfide	[no description available]	medium	1	0	aliphatic sulfide	algal metabolite; bacterial xenobiotic metabolite; EC 3.5.1.4 (amidase) inhibitor; Escherichia coli metabolite; marine metabolite
succinic acid	[no description available]	medium	1	0	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
trimethylamine	[no description available]	medium	1	0	methylamines; tertiary amine	Escherichia coli metabolite; human xenobiotic metabolite
uracil	[no description available]	medium	1	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
phenytoin	[no description available]	medium	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
acetaminophen	[no description available]	medium	1	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
theophylline	[no description available]	medium	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
aspirin	[no description available]	medium	1	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
atrazine	[no description available]	medium	1	0	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic
barbital	[no description available]	medium	1	0	barbiturates	drug allergen
benzocaine	[no description available]	medium	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
bay h 4502	[no description available]	medium	1	0	biphenyls; imidazoles
bromazepam	[no description available]	medium	1	0	organic molecular entity
chlorpromazine	[no description available]	medium	1	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
desipramine	[no description available]	medium	1	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
diazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
ddt	[no description available]	medium	1	0	benzenoid aromatic compound; chlorophenylethane; monochlorobenzenes; organochlorine insecticide	bridged diphenyl acaricide; carcinogenic agent; endocrine disruptor; persistent organic pollutant
diuron	[no description available]	medium	1	0	3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene	environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic
fenbufen	[no description available]	medium	1	0	4-oxo monocarboxylic acid; biphenyls	non-steroidal anti-inflammatory drug
fluconazole	[no description available]	medium	1	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flurbiprofen	[no description available]	medium	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
ibuprofen	[no description available]	medium	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
lidocaine	[no description available]	medium	1	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
imipramine	[no description available]	medium	1	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
indomethacin	[no description available]	medium	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
indoprofen	[no description available]	medium	1	0	gamma-lactam; isoindoles; monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
2-propanol	[no description available]	medium	1	0	secondary alcohol; secondary fatty alcohol	protic solvent
ketoprofen	[no description available]	medium	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
lorazepam	[no description available]	medium	1	0	benzodiazepine
nevirapine	[no description available]	medium	1	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nifedipine	[no description available]	medium	1	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
oxazepam	[no description available]	medium	1	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
perphenazine	[no description available]	medium	1	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin	[no description available]	medium	1	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenobarbital	[no description available]	medium	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
procaine	[no description available]	medium	1	0	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
promazine	[no description available]	medium	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
thioridazine	[no description available]	medium	1	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
trifluoperazine	[no description available]	medium	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
triflupromazine	[no description available]	medium	1	0	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
corticosterone	[no description available]	medium	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
prednisone	[no description available]	medium	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
chloramphenicol	[no description available]	medium	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
mannitol	[no description available]	medium	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
1,1,1-trichloroethane	[no description available]	medium	1	0	chloroethanes	polar solvent
ethylamine	[no description available]	medium	1	0	primary aliphatic amine	human metabolite
nitromethane	[no description available]	medium	1	0	primary nitroalkane; volatile organic compound	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; explosive; NMR chemical shift reference compound; polar aprotic solvent
tert-butyl alcohol	[no description available]	medium	1	0	tertiary alcohol	human xenobiotic metabolite
methylethyl ketone	[no description available]	medium	1	0	butanone; dialkyl ketone; methyl ketone; volatile organic compound	bacterial metabolite; polar aprotic solvent
trichloroethylene	[no description available]	medium	1	0	chloroethenes	inhalation anaesthetic; mouse metabolite
methyl acetate	[no description available]	medium	1	0	acetate ester; methyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; fragrance; polar aprotic solvent
nitroethane	[no description available]	medium	1	0	primary nitroalkane
fluorene	[no description available]	medium	1	0	ortho-fused polycyclic arene; ortho-fused tricyclic hydrocarbon
hexamethylbenzene	[no description available]	medium	1	0	methylbenzene
quinoline	[no description available]	medium	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines
diphenyl	[no description available]	medium	1	0	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative
benzidine	[no description available]	medium	1	0	biphenyls; substituted aniline	carcinogenic agent
methyl benzoate	[no description available]	medium	1	0	benzoate ester; methyl ester	insect attractant; metabolite
benzotrifluoride	[no description available]	medium	1	0	(trifluoromethyl)benzenes; fluorohydrocarbon	environmental contaminant; NMR chemical shift reference compound; solvent
butylphen	[no description available]	medium	1	0	phenols	allergen
carvone	[no description available]	medium	1	0	botanical anti-fungal agent; carvones	allergen
4-chloroaniline	[no description available]	medium	1	0	chloroaniline; monochlorobenzenes
propionitrile	[no description available]	medium	1	0	aliphatic nitrile; volatile organic compound	polar aprotic solvent
pentane	[no description available]	medium	1	0	alkane; volatile organic compound	non-polar solvent; refrigerant
dimethoxymethane	[no description available]	medium	1	0	acetal; diether
tetrahydrofuran	[no description available]	medium	1	0	cyclic ether; oxolanes; saturated organic heteromonocyclic parent; volatile organic compound	polar aprotic solvent
furan	[no description available]	medium	1	0	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
thiophenes	[no description available]	medium	1	0	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
n-hexane	[no description available]	medium	1	0	alkane; volatile organic compound	neurotoxin; non-polar solvent
cyclohexane	[no description available]	medium	1	0	cycloalkane; volatile organic compound	non-polar solvent
cyclohexene	[no description available]	medium	1	0	cycloalkene
morpholine	[no description available]	medium	1	0	morpholines; saturated organic heteromonocyclic parent	NMR chemical shift reference compound
ethyl-p-hydroxybenzoate	[no description available]	medium	1	0	ethyl ester; paraben	antifungal agent; antimicrobial food preservative; phytoestrogen; plant metabolite
3-nitrobenzoic acid	[no description available]	medium	1	0
2-naphthol	[no description available]	medium	2	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
ephedrine	[no description available]	medium	1	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
4-chloroacetanilide	[no description available]	medium	1	0	acetamides; monochlorobenzenes
1-chloropropane	[no description available]	medium	1	0
2,3-dichlorophenol	[no description available]	medium	1	0
methyl butyrate	[no description available]	medium	1	0	fatty acid ester
decachlorobiphenyl	[no description available]	medium	1	0	pentachlorobenzenes; polychlorobiphenyl
desmedipham	[no description available]	medium	1	0	carbamate ester	agrochemical; environmental contaminant; herbicide; xenobiotic
menthone	[no description available]	medium	1	0	menthone
dimethylacetamide	[no description available]	medium	1	0	acetamides; monocarboxylic acid amide	human metabolite
pyrene	[no description available]	medium	1	0	ortho- and peri-fused polycyclic arene	fluorescent probe; persistent organic pollutant
fenoxycarb	[no description available]	medium	1	0	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic
fenclofenac	[no description available]	medium	1	0	aromatic ether
naproxen	[no description available]	medium	1	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
camphora	[no description available]	medium	1	0	camphor
atropine	[no description available]	medium	1	0
(+)-limonene	[no description available]	medium	1	0	limonene	plant metabolite
griseofulvin	[no description available]	medium	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
cocaine	[no description available]	medium	1	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylstilbestrol	[no description available]	medium	1	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
sulindac	[no description available]	medium	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
dinoprostone	[no description available]	medium	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
codeine	[no description available]	medium	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
morphine	[no description available]	medium	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
nifuroxime	[no description available]	medium	1	0
nitrofurantoin	[no description available]	medium	1	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
warfarin	[no description available]	medium	1	0	benzenes; hydroxycoumarin; methyl ketone
guanine	[no description available]	medium	1	0	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
allopurinol	[no description available]	medium	1	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
mafenide	[no description available]	medium	46	0	aromatic amine
sulfaguanidine	[no description available]	medium	1	0	sulfonamide antibiotic	antiinfective agent
carzenide	[no description available]	medium	46	0	sulfonamide
4-amino-6-chloro-1,3-benzenedisulfonamide	[no description available]	medium	44	0	sulfonamide
2,4-disulfamyl-5-trifluoromethylaniline	[no description available]	medium	43	0
4-(2-aminoethyl)benzenesulfonamide	[no description available]	medium	44	0
acetazolamide	[no description available]	medium	44	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
dichlorphenamide	[no description available]	medium	42	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
ethoxzolamide	[no description available]	medium	42	0	aromatic ether; benzothiazoles; sulfonamide	antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
methazolamide	[no description available]	medium	42	0	sulfonamide; thiadiazoles
sulpiride	[no description available]	medium	41	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
benzolamide	[no description available]	medium	42	0
brinzolamide	[no description available]	medium	42	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
5-amino-1,3,4-thiadiazole-2-sulfonamide	[no description available]	medium	42	0
chlorzolamide	[no description available]	medium	22	0
dorzolamide	[no description available]	medium	42	0	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
topiramate	[no description available]	medium	42	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
6-hydroxybenzothiazide-2-sulfonamide	[no description available]	medium	13	0
2-benzothiazolesulfonamide	[no description available]	medium	1	0	benzothiazoles; sulfonamide
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide	[no description available]	medium	40	0	chloroindole; organochlorine compound; sulfonamide	antineoplastic agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor
zonisamide	[no description available]	medium	38	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
celecoxib	[no description available]	medium	35	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
saccharin	[no description available]	medium	30	0	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic
neoprontosil	[no description available]	medium	1	0
valdecoxib	[no description available]	medium	35	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
2,6-dibromosulfanilamide	[no description available]	medium	5	0
sulthiame	[no description available]	medium	30	0	organic molecular entity
2,3-dihydroxybenzoic acid	[no description available]	medium	1	0	dihydroxybenzoic acid	human xenobiotic metabolite; plant metabolite
protocatechuic acid	[no description available]	medium	1	0	catechols; dihydroxybenzoic acid	antineoplastic agent; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; human xenobiotic metabolite; plant metabolite
catechol	[no description available]	medium	2	0	catechols	allelochemical; genotoxin; plant metabolite
guaiacol	[no description available]	medium	2	0	guaiacols	disinfectant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; expectorant; plant metabolite
picolinic acid	[no description available]	medium	1	0	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material
quinolinic acid	[no description available]	medium	1	0	pyridinedicarboxylic acid	Escherichia coli metabolite; human metabolite; mouse metabolite; NMDA receptor agonist
1,10-phenanthroline	[no description available]	medium	1	0	phenanthroline	EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
beta-resorcylic acid	[no description available]	medium	1	0
pyrithione	[no description available]	medium	1	0	monohydroxypyridine; pyridinethione	ionophore
oxyquinoline	[no description available]	medium	2	0	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
acetohydroxamic acid	[no description available]	medium	2	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
cloxyquin	[no description available]	medium	1	0	organochlorine compound; quinolines
fusaric acid	[no description available]	medium	1	0	aromatic carboxylic acid; pyridines
2,5-dihydroxybenzoic acid	[no description available]	medium	1	0	dihydroxybenzoic acid	EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; fungal metabolite; human metabolite; MALDI matrix material; mouse metabolite
beta-thujaplicin	[no description available]	medium	1	0	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite
kojic acid	[no description available]	medium	1	0	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
aminosalicylic acid	[no description available]	medium	1	0	aminobenzoic acid; phenols	antitubercular agent
salicylamide	[no description available]	medium	1	0	phenols; salicylamides	antirheumatic drug; non-narcotic analgesic
carbostyril	[no description available]	medium	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
3-methylsalicylic acid	[no description available]	medium	1	0	monohydroxybenzoic acid	bacterial xenobiotic metabolite
lawsone	[no description available]	medium	1	0
5-methylsalicylic acid	[no description available]	medium	1	0
quinaldic acid	[no description available]	medium	1	0	quinolinemonocarboxylic acid	human metabolite; Saccharomyces cerevisiae metabolite
2,5-pyridinedicarboxylic acid	[no description available]	medium	1	0	pyridinedicarboxylic acid
maltol	[no description available]	medium	1	0	4-pyranones	metabolite
gamma-resorcylic acid	[no description available]	medium	1	0	dihydroxybenzoic acid	metabolite
dipicolinic acid	[no description available]	medium	1	0	pyridinedicarboxylic acid	bacterial metabolite
tropolone	[no description available]	medium	1	0	alpha-hydroxy ketone; cyclic ketone; enol	bacterial metabolite; fungicide; toxin
1,2-dihydroxynaphthalene	[no description available]	medium	1	0	naphthalenediol	mouse metabolite
8-aminoquinoline	[no description available]	medium	2	0
6-methyluracil	[no description available]	medium	1	0	pyrimidone	metabolite
2-pyrrolecarboxylic acid	[no description available]	medium	1	0	pyrrolecarboxylic acid	plant metabolite
8-hydroxy-2-methylquinoline	[no description available]	medium	1	0	hydroxyquinoline
2-(2'-hydroxyphenyl)benzoxazole	[no description available]	medium	1	0	1,3-benzoxazoles; phenols	geroprotector
3-hydroxypicolinic acid	[no description available]	medium	1	0	monocarboxylic acid; monohydroxypyridine	MALDI matrix material
8-hydroxyquinoline N-oxide	[no description available]	medium	1	0	monohydroxyquinoline; quinoline N-oxide
clopyralid	[no description available]	medium	1	0	organochlorine pesticide; pyridines	herbicide
2-(2-hydroxyphenyl)benzothiazole	[no description available]	medium	1	0	benzothiazoles; phenols	geroprotector
ethyl maltol	[no description available]	medium	1	0	pyranone
2,3-dihydroxypyridine	[no description available]	medium	1	0	dihydroxypyridine
acetylacetone	[no description available]	medium	1	0	beta-diketone
5-fluorosalicylic acid	[no description available]	medium	1	0
pyromeconic acid	[no description available]	medium	2	0
2-hydroxypyrimidine	[no description available]	medium	1	0	hydroxypyrimidine	electron donor; Lewis base
allomaltol	[no description available]	medium	1	0
1-hydroxy-2(1h)-pyridinone	[no description available]	medium	2	0
2,2'-dipicolylamine	[no description available]	medium	1	0
8-hydroxy-2-quinolinecarboxylic acid	[no description available]	medium	2	0	quinolines
3-chloro-2,4-pentanedione	[no description available]	medium	1	0
1-methyl-2-ethyl-3-hydroxypyridin-4-one	[no description available]	medium	1	0
cp094	[no description available]	medium	1	0
1-methyl-3-hydroxypyridine-2-one	[no description available]	medium	2	0
1-ethyl-2-methyl-3-hydroxypyridin-4-one	[no description available]	medium	1	0
2-acetylcyclopentanone	[no description available]	medium	2	0
8-(methylsulfonylamino)quinoline	[no description available]	medium	2	0
1,4,7-triazacyclononane	[no description available]	medium	1	0	azacycloalkane; crown amine; saturated organic heteromonocyclic parent
methylthiouracil	[no description available]	medium	1	0	pyrimidone
4,6-dimethyl-2-thiopyrimidine	[no description available]	medium	1	0
thiouracil	[no description available]	medium	1	0	nucleobase analogue; thiocarbonyl compound	antithyroid drug; metabolite
4-thiouracil	[no description available]	medium	1	0
3-hydroxy-2-methyl-4h-pyran-4-thione	[no description available]	medium	1	0
2,4-diaminohypoxanthine	[no description available]	medium	1	0	hydroxypyrimidine
hydrobromic acid	[no description available]	medium	1	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
hydrochloric acid	[no description available]	medium	1	0	chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
hydrogen sulfide	[no description available]	medium	1	0	gas molecular entity; hydracid; mononuclear parent hydride; sulfur hydride	Escherichia coli metabolite; genotoxin; metabolite; signalling molecule; toxin; vasodilator agent
cyanic acid	[no description available]	medium	1	0	one-carbon compound; pseudohalogen oxoacid
carbonic acid	[no description available]	medium	1	0	carbon oxoacid; chalcocarbonic acid	mouse metabolite
hydrogen cyanide	[no description available]	medium	1	0	hydracid; one-carbon compound	Escherichia coli metabolite; human metabolite; poison
thiocyanic acid	[no description available]	medium	1	0	hydracid; one-carbon compound; organosulfur compound	Escherichia coli metabolite
nitric acid	[no description available]	medium	1	0	nitrogen oxoacid	protic solvent; reagent
sulfurous acid	[no description available]	medium	1	0	sulfur oxoacid
sulfuric acid	[no description available]	medium	1	0	sulfur oxoacid	catalyst
sulfamic acid	[no description available]	medium	1	0	sulfamic acids
benzenearsonic acid	[no description available]	medium	1	0	arsonic acids; organoarsonic acid
hydrofluoric acid	[no description available]	medium	1	0	hydrogen halide; mononuclear parent hydride	NMR chemical shift reference compound
nitrous acid	[no description available]	medium	1	0	nitrogen oxoacid
hydrazoic acid	[no description available]	medium	1	0	nitrogen hydride
hydroiodic acid	[no description available]	medium	1	0	gas molecular entity; hydrogen halide; mononuclear parent hydride	mouse metabolite
benzeneboronic acid	[no description available]	medium	1	0	boronic acids
sulfamide	[no description available]	medium	1	0	sulfamides
hydrochlorothiazide	[no description available]	medium	22	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
sulfadiazine	[no description available]	medium	1	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfapyridine	[no description available]	medium	1	0	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic
ketoconazole	[no description available]	medium	2	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
benzonidazole	[no description available]	medium	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
disulphane	[no description available]	medium	17	0
benzene-1-3-disulfonamide	[no description available]	medium	18	0	sulfonamide
1-(4-chlorophenyl)-3-(4-sulfamoylphenyl)urea	[no description available]	medium	1	0	sulfonamide
n-4-tosylglycine	[no description available]	medium	1	0
imidazole	[no description available]	medium	1	0	imidazole
deferiprone	[no description available]	medium	1	0	4-pyridones	iron chelator; protective agent
barbituric acid	[no description available]	medium	1	0	barbiturates	allergen; xenobiotic
hydantoins	[no description available]	medium	1	0	imidazolidine-2,4-dione
lysidine	[no description available]	medium	1	0
1,2-Dihydroquinolin-2-imine	[no description available]	medium	1	0	aminoquinoline
2-hydroxy benzimidazole	[no description available]	medium	1	0
4-methylimidazole	[no description available]	medium	1	0	imidazoles	carcinogenic agent; reaction intermediate
2-hydroxybenzothiazole	[no description available]	medium	1	0	benzothiazole
serinol	[no description available]	medium	1	0
1-phenylimidazole	[no description available]	medium	1	0
2-mercaptobenzimidazole	[no description available]	medium	1	0
thiohydantoins	[no description available]	medium	1	0
4,5-dihydro-1h-1,2,4-triazol-5-one	[no description available]	medium	1	0
cobaltous chloride	[no description available]	medium	1	0	cobalt salt; inorganic chloride	allergen; calcium channel blocker; sensitiser; two-colour indicator
palladium	[no description available]	medium	1	0	metal allergen; nickel group element atom; platinum group metal atom
lignin	[no description available]	medium	1	0
trientine	[no description available]	medium	1	0	polyazaalkane; tetramine	copper chelator
tacrine	[no description available]	medium	1	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
indium	[no description available]	medium	1	0	boron group element atom
pyrroles	[no description available]	medium	2	0	pyrrole; secondary amine
thiopyran	[no description available]	medium	1	0
silver	[no description available]	medium	1	0	copper group element atom; elemental silver	Escherichia coli metabolite
xanthenes	[no description available]	medium	1	0	xanthene
chalcone	[no description available]	medium	1	0	chalcone	EC 3.2.1.1 (alpha-amylase) inhibitor
alkenes	[no description available]	medium	1	0
deoxycytidine	[no description available]	medium	1	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
gemcitabine	[no description available]	medium	1	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
quinoxalines	[no description available]	medium	1	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
sulfaphenazole	[no description available]	medium	1	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
phenyl acetate	[no description available]	medium	1	0	benzenes; phenyl acetates
lithium acetate	[no description available]	medium	1	0	acetate salt; organic lithium salt
mannich bases	[no description available]	medium	1	0
tetramethylammonium	[no description available]	medium	1	0	quaternary ammonium ion
tetrabutylammonium	[no description available]	medium	1	0	quaternary ammonium ion
pentobarbital	[no description available]	medium	1	0	barbiturates	GABAA receptor agonist
ketamine	[no description available]	medium	1	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
verapamil	[no description available]	medium	1	0	aromatic ether; nitrile; polyether; tertiary amino compound
chloramine-t	[no description available]	medium	3	0	organic sodium salt	allergen; antifouling biocide; disinfectant
acetaldehyde	[no description available]	medium	1	0	aldehyde	carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent
azides	[no description available]	medium	2	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
2-sulfobenzoic acid	[no description available]	medium	1	0
sodium sulfate	[no description available]	medium	1	0	inorganic sodium salt
formaldehyde	[no description available]	medium	2	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
paclitaxel	[no description available]	medium	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
methyl cinnamate	[no description available]	medium	1	0	methyl cinnamate	antibacterial agent; fungal metabolite; nematicide; plant metabolite
sodium azide	[no description available]	medium	1	0	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
3-fluorophenylalanine	[no description available]	medium	1	0
phenylalanine	[no description available]	medium	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
1-(4-methanesulfonamidophenoxy)-3-(n-methyl-3,4-dichlorophenylethylamino)-2-propanol	[no description available]	low	0	0	sulfonamide
amosulalol	[no description available]	low	0	0	sulfonamide
ampiroxicam	[no description available]	low	0	0	acetal; aminopyridine; benzothiazine; etabonate ester; monocarboxylic acid amide; sulfonamide	analgesic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
amsacrine	[no description available]	low	0	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
azosemide	[no description available]	low	0	0	monochlorobenzenes; sulfonamide; tetrazoles; thiophenes	loop diuretic
bendroflumethiazide	[no description available]	low	0	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzothiazide	[no description available]	low	0	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzylhydrochlorothiazide	[no description available]	low	0	0	benzenes; benzothiadiazine; organochlorine compound; secondary amino compound; sulfonamide
bumetanide	[no description available]	low	0	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
chlorthalidone	[no description available]	low	0	0	isoindoles; monochlorobenzenes; sulfonamide
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide	[no description available]	low	0	0	sulfonamide
e 4031	[no description available]	low	0	0	sulfonamide
famotidine	[no description available]	low	0	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
furosemide	[no description available]	low	0	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
glimepiride	[no description available]	low	0	0	sulfonamide
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide	[no description available]	low	0	0	isoquinolines; sulfonamide
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide	[no description available]	low	0	0	bromobenzenes; isoquinolines; olefinic compound; secondary amino compound; sulfonamide	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
hydroxymethyltolbutamide	[no description available]	low	0	0	benzyl alcohols; sulfonamide; ureas	metabolite
indapamide	[no description available]	low	0	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
metolazone	[no description available]	low	0	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
monodansylcadaverine	[no description available]	low	0	0	aminonaphthalene; primary amino compound; sulfonamide; tertiary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor; fluorochrome; protective agent
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide	[no description available]	low	0	0	naphthalenes; organochlorine compound; primary amino compound; sulfonamide
naratriptan	[no description available]	low	0	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nimesulide	[no description available]	low	0	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	[no description available]	low	0	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide	[no description available]	low	0	0	sulfonamide
phthalylsulfathiazole	[no description available]	low	0	0	1,3-thiazoles; dicarboxylic acid monoamide; sulfonamide antibiotic; sulfonamide
probenecid	[no description available]	low	0	0	benzoic acids; sulfonamide	uricosuric drug
sotalol	[no description available]	low	0	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
SU6656	[no description available]	low	0	0	oxindoles; sulfonamide	antineoplastic agent; Aurora kinase inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
sulfacytine	[no description available]	low	0	0	benzenes; sulfonamide
sulfadimethoxine	[no description available]	low	0	0	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic
sulfamerazine	[no description available]	low	0	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen
sulfameter	[no description available]	low	0	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent; leprostatic drug; renal agent
sulfamethazine	[no description available]	low	0	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic
sulfamethizole	[no description available]	low	0	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole	[no description available]	low	0	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfamethoxypyridazine	[no description available]	low	0	0	pyridazines; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamonomethoxine	[no description available]	low	0	0	benzenes; sulfonamide
sulfanitran	[no description available]	low	0	0	sulfonamide
sulfaquinoxaline	[no description available]	low	0	0	benzenes; sulfonamide
sulfathiazole	[no description available]	low	0	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfisomidine	[no description available]	low	0	0	pyrimidines; sulfonamide antibiotic; sulfonamide	antiinfective agent
sulfisoxazole	[no description available]	low	0	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulfoxone	[no description available]	low	0	0	sulfonamide
sumatriptan	[no description available]	low	0	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
delavirdine	[no description available]	low	0	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
n-methyl-n-nitrosotoluene-p-sulfonamide	[no description available]	low	0	0	sulfonamide
sulfachlorpyridazine	[no description available]	low	0	0	organochlorine compound; pyridazines; sulfonamide	antibacterial drug; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
acetyl sulfisoxazole	[no description available]	low	0	0	benzenes; sulfonamide
sulfaethidole	[no description available]	low	0	0	benzenes; sulfonamide
sulfalene	[no description available]	low	0	0	pyrazines; sulfonamide antibiotic; sulfonamide
thioproperazine	[no description available]	low	0	0	N-alkylpiperazine; N-methylpiperazine; phenothiazines; sulfonamide	phenothiazine antipsychotic drug
carbutamide	[no description available]	low	0	0	benzenes; sulfonamide
glymidine	[no description available]	low	0	0	diether; pyrimidines; sulfonamide	hypoglycemic agent
thiazosulfone	[no description available]	low	0	0	sulfonamide
glybuthiazol	[no description available]	low	0	0	benzenes; sulfonamide
sulfanilylurea	[no description available]	low	0	0	benzenes; sulfonamide
metahexamide	[no description available]	low	0	0	benzenes; sulfonamide
clopamide	[no description available]	low	0	0	sulfonamide
tolcyclamide	[no description available]	low	0	0	sulfonamide
sulfamoxole	[no description available]	low	0	0	oxazole; sulfonamide antibiotic; sulfonamide	antimicrobial agent; drug allergen
sulfaethoxypyridazine	[no description available]	low	0	0	sulfonamide	antibacterial agent
4-((diethylamino)sulfonyl)benzoic acid	[no description available]	low	0	0	sulfonamide
dinsed	[no description available]	low	0	0	sulfonamide
amidephrine	[no description available]	low	0	0	sulfonamide
sulfadoxine	[no description available]	low	0	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
hydroxyhexamide	[no description available]	low	0	0	sulfonamide
asulam	[no description available]	low	0	0	carbamate ester; primary amino compound; substituted aniline; sulfonamide	agrochemical; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; herbicide; xenobiotic
n-butylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide	neurotoxin; plant metabolite
oryzalin	[no description available]	low	0	0	aromatic amine; C-nitro compound; sulfonamide; tertiary amino compound	agrochemical; antimitotic; herbicide
glisoxepide	[no description available]	low	0	0	sulfonamide
perfluidone	[no description available]	low	0	0	sulfonamide
mefluidide	[no description available]	low	0	0	sulfonamide
clorsulon	[no description available]	low	0	0	benzenes; sulfonamide
agreal	[no description available]	low	0	0	sulfonamide
n-acetylsulfapyridine	[no description available]	low	0	0	sulfonamide
tirofiban	[no description available]	low	0	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
n(4)-acetylsulfadiazine	[no description available]	low	0	0	acetamides; pyrimidines; sulfonamide	marine xenobiotic metabolite
amprenavir	[no description available]	low	0	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
n(4)-acetylsulfamethoxazole	[no description available]	low	0	0	isoxazoles; sulfonamide	drug metabolite; marine xenobiotic metabolite
glisentide	[no description available]	low	0	0	sulfonamide
ebrotidine	[no description available]	low	0	0	sulfonamide
N(4)-acetylsulfathiazole	[no description available]	low	0	0	1,3-thiazoles; acetamides; sulfonamide	marine xenobiotic metabolite
piloty's acid	[no description available]	low	0	0	sulfonamide
perfluorooctanesulfonamide	[no description available]	low	0	0	perfluorinated compound; sulfonamide	persistent organic pollutant
uk 68798	[no description available]	low	0	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
glyclopyramide	[no description available]	low	0	0	sulfonamide
fluoresone	[no description available]	low	0	0	sulfonamide
4-chloro-5-sulfamoylanthranilic acid	[no description available]	low	0	0	benzenes; sulfonamide
sulfluramid	[no description available]	low	0	0	sulfonamide	acaricide; environmental contaminant; insecticide; xenobiotic
8-(4-tolylsulfonylamino)quinoline	[no description available]	low	0	0	sulfonamide
n-(2,4-dichloro-5-(4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1h-1,2,4-triazol-1-yl)phenyl)methanesulfonamide	[no description available]	low	0	0	dichlorobenzene; organofluorine compound; sulfonamide; triazoles	agrochemical; EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor; herbicide
cloransulam-methyl	[no description available]	low	0	0	methyl ester; monochlorobenzenes; organofluorine compound; sulfonamide; triazolopyrimidines	agrochemical; EC 2.2.1.6 (acetolactate synthase) inhibitor; herbicide
sdds	[no description available]	low	0	0	benzenes; sulfonamide
4-chlorobenzenesulfonylurea	[no description available]	low	0	0	sulfonamide
n-(2,6-difluorophenyl)-5-methyl(1,2,4)-triazol(1,5-a)pyrimidine-2-sulfonamide	[no description available]	low	0	0	sulfonamide
flazasulfuron	[no description available]	low	0	0	pyridines; sulfonamide
4-methyl-N-(phenylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
bosentan anhydrous	[no description available]	low	0	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
sulfamethoxazole hydroxylamine	[no description available]	low	0	0	isoxazoles; sulfonamide	allergen; metabolite
gr 113808	[no description available]	low	0	0	indolyl carboxylate ester; piperidines; sulfonamide	serotonergic antagonist
ym 12617	[no description available]	low	0	0	aromatic ether; secondary amino compound; sulfonamide
dansyllysine	[no description available]	low	0	0	L-lysine derivative; non-proteinogenic L-alpha-amino acid; sulfonamide	epitope
almotriptan	[no description available]	low	0	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
4-nitrososulfamethoxazole	[no description available]	low	0	0	isoxazoles; nitroso compound; sulfonamide	allergen; metabolite
cki 7	[no description available]	low	0	0	isoquinolines; organochlorine compound; primary amino compound; sulfonamide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
fosamprenavir	[no description available]	low	0	0	sulfonamide	prodrug
metipamide	[no description available]	low	0	0	sulfonamide
jte 522	[no description available]	low	0	0	1,3-oxazoles; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor
carboxytolbutamide	[no description available]	low	0	0	sulfonamide
tevenel	[no description available]	low	0	0	sulfonamide
sulfachlorpyrazine	[no description available]	low	0	0	sulfonamide
n(4)-acetylsulfadimethoxine	[no description available]	low	0	0	acetamides; pyrimidines; sulfonamide	marine xenobiotic metabolite
dronedarone	[no description available]	low	0	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
darunavir	[no description available]	low	0	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
cimicoxib	[no description available]	low	0	0	aromatic ether; imidazoles; organochlorine compound; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
dabuzalgron	[no description available]	low	0	0	aromatic ether; imidazoles; monochlorobenzenes; sulfonamide	alpha-adrenergic agonist
N-cyclooctyl-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
tolpyrramide	[no description available]	low	0	0	sulfonamide
acetic acid [2-[acetyl-(4-methylphenyl)sulfonylamino]phenyl] ester	[no description available]	low	0	0	sulfonamide
1-(benzenesulfonyl)indole	[no description available]	low	0	0	sulfonamide
tosylphenylalanyl chloromethyl ketone	[no description available]	low	0	0	alpha-chloroketone; sulfonamide	alkylating agent; serine proteinase inhibitor
rosuvastatin	[no description available]	low	0	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
bms 214662	[no description available]	low	0	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
N-[4-(methanesulfonamido)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
prinomastat	[no description available]	low	0	0	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor
glucosulfone	[no description available]	low	0	0	sulfonamide
1-[1-(benzenesulfonyl)-3-pyrrolyl]ethanone	[no description available]	low	0	0	sulfonamide
1-(4-bromo-2,5-dimethoxyphenyl)sulfonylazepane	[no description available]	low	0	0	sulfonamide
1-(4-chloro-3-methoxyphenyl)sulfonylazepane	[no description available]	low	0	0	sulfonamide
6-[(4-methylphenyl)sulfonyl]-6-azabicyclo[3.2.1]octane	[no description available]	low	0	0	sulfonamide
N-cyclopentyl-4-[[4-[2-furanyl(oxo)methyl]-1-piperazinyl]sulfonyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N4-cyclohexyl-N1-ethyl-N4-(2-pyridinylmethyl)benzene-1,4-disulfonamide	[no description available]	low	0	0	sulfonamide
2-[cyclohexyl-(2,4,6-trimethylphenyl)sulfonylamino]-N-(3-pyridinylmethyl)acetamide	[no description available]	low	0	0	sulfonamide
1-(3-chloro-4-methoxyphenyl)sulfonyl-N-(3-pyridinyl)-3-piperidinecarboxamide	[no description available]	low	0	0	sulfonamide
N-(3-ethoxyphenyl)-1-(4-methoxyphenyl)sulfonyl-3-piperidinecarboxamide	[no description available]	low	0	0	sulfonamide
N-[4-[[4-(4-methylphenyl)sulfonyl-1,4-diazepan-1-yl]sulfonyl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
N-[2-(2-furanylmethylthio)ethyl]-4-methoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-[2-[1-(4-methoxyphenyl)sulfonyl-2-benzimidazolyl]ethyl]morpholine	[no description available]	low	0	0	sulfonamide
1-(2,5-dimethoxyphenyl)sulfonyl-N-(phenylmethyl)-4-piperidinecarboxamide	[no description available]	low	0	0	sulfonamide
1-[2-chloro-5-(trifluoromethyl)phenyl]sulfonylazepane	[no description available]	low	0	0	sulfonamide
4-[4-[(5,6-dimethyl-1-benzimidazolyl)sulfonyl]phenyl]sulfonylmorpholine	[no description available]	low	0	0	sulfonamide
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(4-methoxyphenyl)sulfonylpiperazine	[no description available]	low	0	0	sulfonamide
4-methyl-N-(pyridin-4-ylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-cyclopropyl-4-(2,3-dihydroindol-1-ylsulfonyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[4-(benzenesulfonyl)phenyl]-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole	[no description available]	low	0	0	sulfonamide
N-(2-furanylmethyl)-2-[(4-methoxyphenyl)sulfonylamino]benzamide	[no description available]	low	0	0	sulfonamide
N-[4-(diethylsulfamoyl)phenyl]-2-(2-oxo-1,3-benzothiazol-3-yl)acetamide	[no description available]	low	0	0	sulfonamide
3-[[4-(1-benzotriazolyl)-1-piperidinyl]sulfonyl]-N-cyclopentylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N,N-dimethyl-4-[[4-(5-methyl-1-benzotriazolyl)-1-piperidinyl]sulfonyl]benzamide	[no description available]	low	0	0	sulfonamide
4-(4-methoxyphenyl)sulfonyl-N-(phenylmethyl)-1-piperazinecarboxamide	[no description available]	low	0	0	sulfonamide
N-[4-(4-fluorophenyl)-2-thiazolyl]-2-[(4-methylphenyl)sulfonylamino]benzamide	[no description available]	low	0	0	sulfonamide
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide	[no description available]	low	0	0	acetamides; piperidines; pyridines; sulfonamide
3,4,5-trimethoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide	[no description available]	low	0	0	sulfonamide
N-(4-phenylmethoxyphenyl)methanesulfonamide	[no description available]	low	0	0	sulfonamide
3-(diethylsulfamoyl)-N-(1,3,4-thiadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
2-[(4-fluoro-3-methylphenyl)sulfonylamino]acetic acid	[no description available]	low	0	0	sulfonamide
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-thiophenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(2-furanylmethyl)-4-methyl-N-(phenylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-(2-ethylphenoxy)-N-(4-sulfamoylphenyl)acetamide	[no description available]	low	0	0	sulfonamide
N-(3-chloro-4-hydroxy-2,5-dimethylphenyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2,4,6-trimethyl-n-(meta-3-trifluoromethylphenyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[2-(1-cyclohexenyl)ethyl]-2,5-dimethoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(1-ethyl-5-benzimidazolyl)-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-methyl-N-(5,6,7,8-tetrahydronaphthalen-1-yl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-chloro-N-(4-hydrazinyl-6-methyl-2-pyrimidinyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-amino-N-(4-ethoxyphenyl)benzenesulfonamide	[no description available]	low	0	0	benzenes; sulfonamide
1-(2-nitrophenyl)sulfonylpiperidine	[no description available]	low	0	0	sulfonamide
N,4-dimethyl-N-(4-methylphenyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2,3,4-trimethyl-N-(3-pyridinyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[[4-(1-pyrrolidinylsulfonyl)phenyl]hydrazinylidene]propanedinitrile	[no description available]	low	0	0	sulfonamide
N-[1-(benzenesulfonyl)-2,2-dichloroethenyl]acetamide	[no description available]	low	0	0	sulfonamide
2-(4-fluoro-N-methylsulfonylanilino)-N-(3-methylphenyl)acetamide	[no description available]	low	0	0	sulfonamide
4-chloro-3-ethoxy-N-(4-ethylphenyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
1-(3-chlorophenyl)sulfonylpyrrolidine	[no description available]	low	0	0	sulfonamide
1-cyclopropyl-3-(4-sulfamoylphenyl)thiourea	[no description available]	low	0	0	sulfonamide
N-[3-[methyl(methylsulfonyl)amino]phenyl]-2-phenoxyacetamide	[no description available]	low	0	0	sulfonamide
4-[methyl(methylsulfonyl)amino]-N-(2-phenylethyl)benzamide	[no description available]	low	0	0	sulfonamide
2-(2,6-dichloroanilino)-3-pyridinesulfonamide	[no description available]	low	0	0	pyridines; sulfonamide
4-(4-chloroanilino)-3-pyridinesulfonamide	[no description available]	low	0	0	pyridines; sulfonamide
1-ethyl-3-(4-methylphenyl)sulfonylthiourea	[no description available]	low	0	0	sulfonamide
6-chloro-N-(2-hydroxyphenyl)-3-pyridinesulfonamide	[no description available]	low	0	0	pyridines; sulfonamide
5-chloro-2-methoxy-N,N,4-trimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[(2,5-dimethoxyphenyl)sulfonyl-methylamino]acetic acid	[no description available]	low	0	0	sulfonamide
N-(2-ethylphenyl)-2-methoxy-5-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-ethoxy-N-(4-fluorophenyl)-2,3-dimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[2-(1-cyclohexenyl)ethyl]-4-[methyl(methylsulfonyl)amino]benzamide	[no description available]	low	0	0	sulfonamide
1-(2,5-dimethoxyphenyl)sulfonyl-4-ethylpiperazine	[no description available]	low	0	0	sulfonamide
N-[2-(methylthio)phenyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-(4-methoxyphenyl)-4-(methylthio)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-methoxy-5-propan-2-yl-N-(2-pyridinyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2,3,5,6-tetramethyl-N-(2-methyl-1,3-benzothiazol-5-yl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[4-chloro-2-methyl-5-(2-pyridinylsulfamoyl)phenoxy]acetamide	[no description available]	low	0	0	sulfonamide
N-(3-chlorophenyl)-N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[4-(6-methyl-1,3-benzothiazol-2-yl)phenyl]-2-(3-methyl-N-methylsulfonylanilino)acetamide	[no description available]	low	0	0	sulfonamide
2-[(5-bromo-2-thiophenyl)sulfonylamino]-N-(2-furanylmethyl)benzamide	[no description available]	low	0	0	sulfonamide
N-[4-[(2,6-dimethoxy-4-pyrimidinyl)sulfamoyl]phenyl]butanamide	[no description available]	low	0	0	sulfonamide
2-(3-pyridinyl)-4-[4-(1-pyrrolidinylsulfonyl)phenyl]thiazole	[no description available]	low	0	0	sulfonamide
5-bromo-6-chloro-N-(4-methyl-2-pyridinyl)-3-pyridinesulfonamide	[no description available]	low	0	0	pyridines; sulfonamide
4-(4-fluorophenyl)sulfonyl-2-(2-furanyl)-N-phenyl-5-oxazolamine	[no description available]	low	0	0	sulfonamide
2-[[4-(4-methylphenyl)sulfonyl-1-piperazinyl]methyl]-4-propan-2-ylphenol	[no description available]	low	0	0	sulfonamide
ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate	[no description available]	low	0	0	carbamate ester; sulfonamide
N-[(2-chlorophenyl)methyl]-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide	[no description available]	low	0	0	sulfonamide
N-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-thiophen-2-ylacetamide	[no description available]	low	0	0	sulfonamide
2-[methyl-(2,4,6-trimethylphenyl)sulfonylamino]-N-(2-pyridinylmethyl)acetamide	[no description available]	low	0	0	sulfonamide
2-[(4-ethoxyphenyl)sulfonylamino]-N-(2-furanylmethyl)benzamide	[no description available]	low	0	0	sulfonamide
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine	[no description available]	low	0	0	sulfonamide
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine	[no description available]	low	0	0	sulfonamide
N-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide	[no description available]	low	0	0	sulfonamide
N-[4-(1-piperidinylsulfonyl)phenyl]-2-thiophenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(1,3-benzothiazol-2-yl)-2-[methyl-(4-methylphenyl)sulfonylamino]acetamide	[no description available]	low	0	0	sulfonamide
1-cyclohexyl-3-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]urea	[no description available]	low	0	0	sulfonamide
N-(5-chloro-2-hydroxyphenyl)-1,3-dimethyl-2-oxo-5-benzimidazolesulfonamide	[no description available]	low	0	0	sulfonamide
2,5-dichloro-4-ethoxy-N-(2-pyridinylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-ethoxy-2,3,5-trimethyl-N-(3-pyridinylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
3-(1-piperidinylsulfonyl)-N-(2-thiazolyl)benzamide	[no description available]	low	0	0	sulfonamide
4-chloro-3-(1-piperidinylsulfonyl)-N-(2-thiazolyl)benzamide	[no description available]	low	0	0	sulfonamide
2-[N-(benzenesulfonyl)-4-ethoxyanilino]-N-(2-methoxyphenyl)acetamide	[no description available]	low	0	0	sulfonamide
1-(2,5-dimethoxyphenyl)sulfonyl-4-(phenylmethyl)piperazine	[no description available]	low	0	0	sulfonamide
4-[(4-chlorophenyl)methyl-methylsulfonylamino]-N-(2-pyridinylmethyl)benzamide	[no description available]	low	0	0	sulfonamide
5-bromo-2-methoxy-N-(3-methyl-2-pyridinyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
pyrabactin	[no description available]	low	0	0	naphthalenes; organobromine compound; pyridines; sulfonamide	abscisic acid receptor agonist; hormone; plant growth regulator
2-(4-methoxyphenyl)-N-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
1,4-bis[(4-methoxy-2-methylphenyl)sulfonyl]-1,4-diazepane	[no description available]	low	0	0	sulfonamide
N-(2-furanylmethyl)-4-(1-pyrrolidinylsulfonyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-(benzenesulfonyl)-N-methyl-N-phenyl-1-piperazinecarboxamide	[no description available]	low	0	0	sulfonamide
2-(3-ethylphenoxy)-N-[4-(2-pyridinylsulfamoyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
N-[[1-(benzenesulfonyl)-4-piperidinyl]methyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
1-(1,3-benzodioxol-5-yl)-3-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]urea	[no description available]	low	0	0	sulfonamide
1-(1,3-benzodioxol-5-yl)-3-[4-[(phenylmethyl)sulfamoyl]phenyl]urea	[no description available]	low	0	0	sulfonamide
1,3-diethyl-6-methyl-N-(2-methylphenyl)-2-oxo-5-benzimidazolesulfonamide	[no description available]	low	0	0	sulfonamide
N-(1,3-benzodioxol-5-ylmethyl)-4-methyl-3-(1-piperidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
3-(1-azepanylsulfonyl)-N-(3-isoxazolyl)-4-methylbenzamide	[no description available]	low	0	0	sulfonamide
1-methylsulfonyl-N-(6,7,8,9-tetrahydrodibenzofuran-2-yl)-2,3-dihydroindole-5-sulfonamide	[no description available]	low	0	0	sulfonamide
2-[2-chloro-4-(2,3-dihydroindol-1-ylsulfonyl)phenoxy]-N-(2-pyridinylmethyl)acetamide	[no description available]	low	0	0	sulfonamide
1-(4-bromo-3-ethoxyphenyl)sulfonyl-3,5-dimethylpyrazole	[no description available]	low	0	0	sulfonamide
N-(4-hydroxy-3,5-dimethylphenyl)-2,5-dimethyl-3-thiophenesulfonamide	[no description available]	low	0	0	sulfonamide
5-[(5-tert-butyl-2,3-dimethylphenyl)sulfonylamino]-2-hydroxybenzoic acid	[no description available]	low	0	0	sulfonamide
1-(4-chloro-2,5-dimethoxyphenyl)sulfonylbenzotriazole	[no description available]	low	0	0	sulfonamide
2-[4-chloro-5-(cyclopentylsulfamoyl)-2-methylphenoxy]-N-cyclohexylacetamide	[no description available]	low	0	0	sulfonamide
2-(1,3-benzothiazol-2-ylthio)-N-(4-methylphenyl)sulfonylacetamide	[no description available]	low	0	0	sulfonamide
2,4-dichloro-5-(diethylsulfamoyl)-N-(1,3,4-thiadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide	[no description available]	low	0	0	sulfonamide
N-(2-methyl-1,3-benzothiazol-6-yl)-4-(4-morpholinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
4-(dimethylsulfamoyl)-N-(4-thiophen-2-yl-2-thiazolyl)benzamide	[no description available]	low	0	0	sulfonamide
2-[1-(4-tert-butylphenyl)sulfonyl-4-piperidinyl]-6-chloro-1H-benzimidazole	[no description available]	low	0	0	sulfonamide
2-[[5-(1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-[4-(1-pyrrolidinylsulfonyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
4-[[3-[(2-chlorophenyl)methyl]-5-cyclopropyl-7-triazolo[4,5-d]pyrimidinyl]amino]-N,N-dimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
7-methyl-2-[4-(4-methylphenyl)sulfonyl-1,4-diazepan-1-yl]-3-quinolinecarbonitrile	[no description available]	low	0	0	sulfonamide
6-amino-5-(benzenesulfonyl)-2-methoxy-3-pyridinecarbonitrile	[no description available]	low	0	0	sulfonamide
6-amino-5-(4-chlorophenyl)sulfonyl-2-oxo-1H-pyridine-3-carbonitrile	[no description available]	low	0	0	sulfonamide
2-[benzenesulfonyl(2-pyridinyl)amino]acetic acid	[no description available]	low	0	0	sulfonamide
2-[(4-chlorophenyl)sulfonyl-(2-pyridinyl)amino]acetic acid	[no description available]	low	0	0	sulfonamide
2,5-dichloro-N-(1,5,6-trimethyl-4-benzimidazolyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[(4-fluorophenyl)sulfonyl-(2-pyridinyl)amino]-N-phenylacetamide	[no description available]	low	0	0	sulfonamide
5-[1-(benzenesulfonyl)-3-pyrazolyl]-2-phenylthiazole	[no description available]	low	0	0	sulfonamide
5-[1-(4-fluorophenyl)sulfonyl-3-pyrazolyl]-2-phenylthiazole	[no description available]	low	0	0	sulfonamide
N-[1-[(3,4-dichlorophenyl)methyl]-6-oxo-3-pyridinyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-(benzenesulfonylmethyl)-5-(4-chlorophenyl)cyclohexane-1,3-dione	[no description available]	low	0	0	sulfonamide
1-(benzenesulfonyl)-3-pyrazolidinone	[no description available]	low	0	0	sulfonamide
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-methyl-4-pyrazolesulfonamide	[no description available]	low	0	0	sulfonamide
N-(4-methoxyphenyl)-2-(3-methylphenoxy)-N-(4-methylphenyl)sulfonylacetamide	[no description available]	low	0	0	sulfonamide
N-[4-(4-fluorophenyl)-2-thiazolyl]-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[[[4-(diethylsulfamoyl)phenyl]-oxomethyl]amino]-4-methyl-5-thiazolecarboxylic acid ethyl ester	[no description available]	low	0	0	sulfonamide
tosylarginine methyl ester	[no description available]	low	0	0	guanidines; L-arginine ester; methyl ester; sulfonamide
n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	[no description available]	low	0	0	pyrazines; sulfonamide; thiophenes	necroptosis inhibitor; neuroprotective agent
N-[(benzenesulfonylhydrazo)-sulfanylidenemethyl]-4-methylbenzamide	[no description available]	low	0	0	sulfonamide
xl147	[no description available]	low	0	0	aromatic amine; benzothiadiazole; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
7-chloro-2-methyl-4-(4-methylphenyl)sulfonylthiazolo[5,4-b]indole	[no description available]	low	0	0	sulfonamide
N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-[(4-methyl-1-piperidinyl)sulfonyl]benzamide	[no description available]	low	0	0	sulfonamide
N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-[methyl-(phenylmethyl)sulfamoyl]benzamide	[no description available]	low	0	0	sulfonamide
4-(4-bromophenyl)sulfonyl-2-(2-furanyl)-5-(methylthio)oxazole	[no description available]	low	0	0	sulfonamide
4-(4-morpholinylsulfonyl)-N-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
1-[4-(benzenesulfonyl)-1-piperazinyl]-2-[(4-fluorophenyl)thio]ethanone	[no description available]	low	0	0	sulfonamide
4-methoxy-N-(3-methylbutyl)-3-(4-morpholinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
N-(1,3-benzothiazol-2-yl)-3-(2,3-dihydroindol-1-ylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
N-(1H-benzimidazol-2-yl)-3-[phenyl(prop-2-enyl)sulfamoyl]benzamide	[no description available]	low	0	0	sulfonamide
1-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]-2-[(5,7-dimethyl-[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thio]ethanone	[no description available]	low	0	0	sulfonamide
3-[4-(4-morpholinylsulfonyl)phenyl]propanoic acid [2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
2-[(5-chloro-2-thiophenyl)sulfonylamino]-N-(2-furanylmethyl)benzamide	[no description available]	low	0	0	sulfonamide
1-[4-(benzenesulfonyl)-1-piperazinyl]-2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]thio]ethanone	[no description available]	low	0	0	sulfonamide
2,5-difluoro-N-[2-(4-morpholinylmethyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-3-[methyl-(4-methylphenyl)sulfamoyl]benzamide	[no description available]	low	0	0	sulfonamide
N-(2-methyl-1,3-benzothiazol-6-yl)-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
3-[(4-acetyl-1-piperazinyl)sulfonyl]-N-(1H-benzimidazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
3-[(3-hydroxy-5-benzotriazolyl)sulfonylamino]benzoic acid	[no description available]	low	0	0	sulfonamide
3-[(5-chloro-2,4-dimethoxyphenyl)-methylsulfamoyl]-N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
2-(2-fluorophenoxy)-N-[4-(2-furanylmethylsulfamoyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
3-[[[5-[3-(1-piperidinylsulfonyl)phenyl]-1,3,4-oxadiazol-2-yl]thio]methyl]-1,2,3-benzotriazin-4-one	[no description available]	low	0	0	sulfonamide
N-(1H-benzimidazol-2-yl)-3-[methyl-(4-methylphenyl)sulfamoyl]benzamide	[no description available]	low	0	0	sulfonamide
2,6-dichloro-N-[2-(methylthio)-1,3-benzothiazol-6-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-fluoro-3-methoxy-N-(2-pyridinyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(5-ethyl-1,3,4-oxadiazol-2-yl)-4-[methyl(phenyl)sulfamoyl]benzamide	[no description available]	low	0	0	sulfonamide
4-[bis(2-methoxyethyl)sulfamoyl]-N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
4-(dipropylsulfamoyl)-N-[5-[(methylthio)methyl]-1,3,4-oxadiazol-2-yl]benzamide	[no description available]	low	0	0	sulfonamide
4-[butyl(methyl)sulfamoyl]-N-[5-[(methylthio)methyl]-1,3,4-oxadiazol-2-yl]benzamide	[no description available]	low	0	0	sulfonamide
4-[ethyl-(phenylmethyl)sulfamoyl]-N-(5-methyl-1,3,4-oxadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
4-[ethyl-(phenylmethyl)sulfamoyl]-N-[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]benzamide	[no description available]	low	0	0	sulfonamide
4-[bis(2-methylpropyl)sulfamoyl]-N-[5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-yl]benzamide	[no description available]	low	0	0	sulfonamide
1-[4-(benzenesulfonyl)-1-piperazinyl]-2-[(4-methyl-2-thiazolyl)thio]ethanone	[no description available]	low	0	0	sulfonamide
1-[4-(benzenesulfonyl)-1-piperazinyl]-2-[(4-ethyl-5-thiophen-2-yl-1,2,4-triazol-3-yl)thio]ethanone	[no description available]	low	0	0	sulfonamide
N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]-4-nitrobenzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[(5-butyl-1H-1,2,4-triazol-3-yl)thio]-N-(4-sulfamoylphenyl)acetamide	[no description available]	low	0	0	sulfonamide
2-ethoxy-N-[4-(2-pyrimidinylsulfamoyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
N-[4-(dibutylsulfamoyl)phenyl]-2-thiophen-2-ylacetamide	[no description available]	low	0	0	sulfonamide
2,3-dichloro-4-methoxy-N-(3-methoxypropyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[(3-cyano-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-2-yl)thio]-N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
N-(2-furanylmethyl)-2-[4-(propylsulfamoyl)phenoxy]acetamide	[no description available]	low	0	0	sulfonamide
4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide	[no description available]	low	0	0	sulfonamide
4-methyl-N-[2-(phenylmethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[4-chloro-5-(cyclohexylsulfamoyl)-2-methylphenoxy]-N-(1,3,4-thiadiazol-2-yl)acetamide	[no description available]	low	0	0	sulfonamide
N-[2-(cyclohexylthio)ethyl]-4-methyl-3-[(4-methylphenyl)sulfamoyl]benzamide	[no description available]	low	0	0	sulfonamide
1-(3-chlorophenyl)-3-[3-[methyl(methylsulfonyl)amino]phenyl]urea	[no description available]	low	0	0	sulfonamide
N-[4-(cyanomethyl)phenyl]-4-cyclohexylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(4-ethoxyphenyl)-4-[[4-(methylthio)phenyl]sulfonylamino]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-(methanesulfonamido)-N-[2-(phenylmethylthio)ethyl]benzamide	[no description available]	low	0	0	sulfonamide
N-(2-fluorophenyl)-4-methoxy-2,5-dimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[benzenesulfonyl-(phenylmethyl)amino]-N-ethylacetamide	[no description available]	low	0	0	sulfonamide
4-[benzenesulfonyl(methyl)amino]-N-[2-[(4-chlorophenyl)methylthio]ethyl]benzamide	[no description available]	low	0	0	sulfonamide
N-(3,4-dimethyl-2-sulfanylidene-5-thiazolyl)carbamic acid 2-[(2,5-dimethylphenyl)sulfonylamino]ethyl ester	[no description available]	low	0	0	sulfonamide
2-[cyclohexyl-(4-methylphenyl)sulfonylamino]-N-(3-methoxypropyl)acetamide	[no description available]	low	0	0	sulfonamide
N-[4-[(4-sulfamoylphenyl)sulfamoyl]phenyl]cyclopropanecarboxamide	[no description available]	low	0	0	sulfonamide
N-(1H-benzimidazol-2-yl)-4-(dimethylsulfamoyl)benzamide	[no description available]	low	0	0	sulfonamide
1-(3-chlorophenyl)-3-[2-(thiophen-2-ylsulfonylamino)phenyl]urea	[no description available]	low	0	0	sulfonamide
2-[4-methyl-3-(1-piperidinylsulfonyl)phenyl]-1,2-benzothiazol-3-one	[no description available]	low	0	0	sulfonamide
N-(1H-benzimidazol-2-ylmethyl)-3-(1-pyrrolidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
2-[(4-fluoro-2-methylphenyl)sulfonylamino]-N-(3-pyridinylmethyl)benzamide	[no description available]	low	0	0	sulfonamide
2-[(4-cyanophenyl)methylthio]-N-(2-methoxyphenyl)-1,3-benzoxazole-5-sulfonamide	[no description available]	low	0	0	sulfonamide
2-[[5-(4-methylanilino)-1,3,4-thiadiazol-2-yl]thio]-N-[4-(4-morpholinylsulfonyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
3-(1-azepanylsulfonyl)-4-chloro-N-(1H-1,2,4-triazol-5-yl)benzamide	[no description available]	low	0	0	sulfonamide
sr 3335	[no description available]	low	0	0	sulfonamide
N-(1H-benzimidazol-2-ylmethyl)-4-(1-pyrrolidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
2-[(4-chlorophenyl)methylthio]-5-[3-(1-piperidinylsulfonyl)phenyl]-1,3,4-oxadiazole	[no description available]	low	0	0	sulfonamide
4-chloro-3-[(4-chlorophenyl)sulfamoyl]-N-(1H-1,2,4-triazol-5-yl)benzamide	[no description available]	low	0	0	sulfonamide
1-(2-fluorophenyl)-1-cyclopentanecarboxylic acid [2-oxo-2-(4-sulfamoylanilino)ethyl] ester	[no description available]	low	0	0	sulfonamide
3-[(4-methyl-1-piperazinyl)sulfonyl]-N-(4-phenyl-2-thiazolyl)benzamide	[no description available]	low	0	0	sulfonamide
N-(2-methoxyphenyl)-2-(2-oxopropylthio)-1,3-benzoxazole-5-sulfonamide	[no description available]	low	0	0	sulfonamide
2-[5-(1-pyrrolidinylsulfonyl)-2-thiophenyl]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide	[no description available]	low	0	0	sulfonamide
1-(4-fluorophenyl)-1-cyclopentanecarboxylic acid [2-oxo-2-(4-sulfamoylanilino)ethyl] ester	[no description available]	low	0	0	sulfonamide
3-(2-chlorophenyl)sulfonylpropanoic acid [2-[(3,5-dichloro-6-methyl-2-pyridinyl)amino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
2-[4-[benzenesulfonyl(methyl)amino]phenoxy]-N-(1,3-benzothiazol-2-yl)acetamide	[no description available]	low	0	0	sulfonamide
N-(6-methoxy-1,3-benzothiazol-2-yl)-3-(4-morpholinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
N-cyclopentyl-3,4-dimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
6-amino-1-(2-methoxyethyl)-N-(4-methylphenyl)sulfonyl-2,4-dioxo-5-pyrimidinecarboxamide	[no description available]	low	0	0	sulfonamide
3-(benzenesulfonyl)propanoic acid [2-[(3,5-dichloro-4-methyl-2-pyridinyl)amino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
N-[[2-cyanoethyl(methyl)amino]-sulfanylidenemethyl]-4-(4-morpholinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
[4-methoxy-3-(4-morpholinylsulfonyl)phenyl]-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methanone	[no description available]	low	0	0	sulfonamide
[4-(4-bromo-2-chlorophenyl)sulfonyl-1-piperazinyl]-(2-sulfanylidene-1H-pyridin-3-yl)methanone	[no description available]	low	0	0	sulfonamide
[1-(4-fluorophenyl)sulfonyl-4-piperidinyl]-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methanone	[no description available]	low	0	0	sulfonamide
N-[(1S)-1-(1H-benzimidazol-2-yl)-2-methylpropyl]-3-(1-pyrrolidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
1-[4-(3-chloro-2,4,6-trifluorophenyl)sulfonyl-1-piperazinyl]ethanone	[no description available]	low	0	0	sulfonamide
1-[4-(benzenesulfonyl)-1-piperazinyl]-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]ethanone	[no description available]	low	0	0	sulfonamide
2-(4-methoxyphenyl)-N-[4-(2-pyrimidinylsulfamoyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
N1-[4-(aminosulfonyl)phenyl]-2,2-dimethylpropanamide	[no description available]	low	0	0	sulfonamide
2-(benzenesulfonylmethyl)-5-(4-methoxyphenyl)cyclohexane-1,3-dione	[no description available]	low	0	0	sulfonamide
2-[bis(2-methylpropoxy)phosphoryl]-3,3,3-trifluoro-2-[(4-methylphenyl)sulfonylamino]propanoic acid ethyl ester	[no description available]	low	0	0	sulfonamide
N1-{3-[2-(2-pyridyl)ethyl]phenyl}-4-chlorobenzene-1-sulfonamide	[no description available]	low	0	0	sulfonamide
ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate	[no description available]	low	0	0	ethyl ester; monochlorobenzenes; organofluorine compound; pyrazoles; sulfonamide
2,3-dichloro-N'-[4-(trifluoromethyl)-2-pyrimidinyl]benzenesulfonohydrazide	[no description available]	low	0	0	sulfonamide
1-(4-ethyl-2-pyridinyl)-3-(4-methylphenyl)sulfonylurea	[no description available]	low	0	0	sulfonamide
1-(3,5-dimethylphenyl)-3-[5-(dimethylsulfamoyl)-2-methylphenyl]urea	[no description available]	low	0	0	sulfonamide
N-{5-[(dimethylamino)sulfonyl]-2-methylphenyl}cyclohexanecarboxamide	[no description available]	low	0	0	sulfonamide
1-tert-butyl-3-[(4-methylphenyl)sulfonylamino]thiourea	[no description available]	low	0	0	sulfonamide
2-[(4-methylphenyl)sulfonylamino]pentanoic acid	[no description available]	low	0	0	sulfonamide
3-methyl-4,7-bis(methylsulfonyl)-3a,5,6,7a-tetrahydro-1H-imidazo[4,5-b]pyrazin-2-one	[no description available]	low	0	0	imidazopyrazine; sulfonamide; ureas
N-(3-acetyl-2-methyl-5-benzofuranyl)-N-(4-chloro-3-nitrophenyl)sulfonylacetamide	[no description available]	low	0	0	sulfonamide
2-[(4-chlorophenyl)thio]-N-[4-[(2,4-dimethylphenyl)sulfamoyl]phenyl]propanamide	[no description available]	low	0	0	sulfonamide
4-chloro-N-[2-(4-morpholinyl)cyclohexyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene	[no description available]	low	0	0	C-nitro compound; sulfonamide; toluenes	bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector
[4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone	[no description available]	low	0	0	sulfonamide
N-[3-(2-furanyl)-3-phenylpropyl]-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[4-(butylsulfamoyl)phenyl]-2-phenyl-2-(phenylthio)acetamide	[no description available]	low	0	0	sulfonamide
N-[2,6-dimethyl-3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N,4-dimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[4-(1-adamantyl)-N-methylsulfonylanilino]acetic acid	[no description available]	low	0	0	sulfonamide
N-[4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-thiazolyl]-2,3-dihydro-1,4-benzodioxin-3-carboxamide	[no description available]	low	0	0	sulfonamide
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-[oxo-[1-(2,4,6-trimethylphenyl)sulfonyl-4-piperidinyl]methyl]-1-piperazinecarboxylic acid ethyl ester	[no description available]	low	0	0	sulfonamide
N,4-dimethyl-N-{2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl}benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]methanesulfonamide	[no description available]	low	0	0	sulfonamide
N-[1-(4-chlorophenyl)sulfonyl-2-pyrrolidinyl]-4-methyl-1-piperazinecarboxamide	[no description available]	low	0	0	sulfonamide
1-[4-(benzenesulfonyl)-1-piperazinyl]-2-[[1-(2-methylpropyl)-2-benzimidazolyl]thio]ethanone	[no description available]	low	0	0	sulfonamide
N-[4-[(4-hydroxyphenyl)-methylsulfamoyl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
6-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-N-ethyl-N-phenyl-3-pyridinesulfonamide	[no description available]	low	0	0	pyridines; sulfonamide
4-chloro-N-(1-propyl-2-benzimidazolyl)-3-(1-pyrrolidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
2,3-dihydro-1,4-benzodioxin-3-yl-[4-(3,4-dimethylphenyl)sulfonyl-1-piperazinyl]methanone	[no description available]	low	0	0	sulfonamide
N-(1-propyl-2-benzimidazolyl)-3-(1-pyrrolidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
1-(benzenesulfonyl)-2-benzimidazolamine	[no description available]	low	0	0	sulfonamide
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine	[no description available]	low	0	0	sulfonamide
sulfatolamide	[no description available]	low	0	0	benzenes; sulfonamide
e 7010	[no description available]	low	0	0	sulfonamide
deracoxib	[no description available]	low	0	0	organofluorine compound; pyrazoles; sulfonamide	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
diclosulam	[no description available]	low	0	0	sulfonamide
N-[2-[(2-chloro-1-oxopropyl)hydrazo]-2-oxoethyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
3-nitro-N-(pyridin-4-ylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[2-[(4-acetamidophenyl)sulfonylamino]-4-thiazolyl]acetic acid ethyl ester	[no description available]	low	0	0	sulfonamide
1-[3-(benzenesulfonyl)-2-(1-piperidinyl)propyl]piperidine	[no description available]	low	0	0	sulfonamide
6-(2-furanyl)-4-[4-(methanesulfonamido)phenyl]-2-oxo-1-cyclohex-3-enecarboxylic acid ethyl ester	[no description available]	low	0	0	sulfonamide
3-(benzenesulfonyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]propanamide	[no description available]	low	0	0	sulfonamide
1-(2-furanylmethyl)-3-[[[4-(4-morpholinylsulfonyl)phenyl]-oxomethyl]amino]thiourea	[no description available]	low	0	0	sulfonamide
N1-butan-2-yl-N4-[2-(3,4-dimethoxyphenyl)ethyl]-N4-(thiophen-2-ylmethyl)benzene-1,4-disulfonamide	[no description available]	low	0	0	sulfonamide
1-(4-chlorophenyl)sulfonyl-N'-[oxo-[4-(1-piperidinylsulfonyl)phenyl]methyl]-4-piperidinecarbohydrazide	[no description available]	low	0	0	sulfonamide
N,N-dimethyl-4-[[3-[3-(5-methyl-2-furanyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]sulfonyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
1-(4-methylphenyl)sulfonyl-3-methylsulfonylimidazolidine	[no description available]	low	0	0	sulfonamide
1-(4-bromophenyl)sulfonyl-4-[(3-methoxyphenyl)methyl]-1,4-diazepane	[no description available]	low	0	0	sulfonamide
2-[[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-oxomethyl]imino-3,4-dimethyl-5-thiazolecarboxylic acid ethyl ester	[no description available]	low	0	0	sulfonamide
1-(4-chlorophenyl)sulfonyl-N-(2-thiazolyl)-1-cyclopropanecarboxamide	[no description available]	low	0	0	sulfonamide
1-methyl-N-[4-(trifluoromethyl)phenyl]-4-imidazolesulfonamide	[no description available]	low	0	0	sulfonamide
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[N-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-methylanilino]acetamide	[no description available]	low	0	0	sulfonamide
N,N-diethyl-4-[[5-oxo-6-(phenylmethyl)-7H-pyrrolo[3,4-b]pyridin-7-yl]amino]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(1,3-benzodioxol-5-yl)-5-bromo-1-[cyclopropyl(oxo)methyl]-N-ethyl-2,3-dihydroindole-7-sulfonamide	[no description available]	low	0	0	sulfonamide
N-(3,4-dimethylphenyl)-2-[N-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-methoxyanilino]acetamide	[no description available]	low	0	0	sulfonamide
3,4-dimethoxy-N-[3-(methylthio)phenyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-methylanilino]acetamide	[no description available]	low	0	0	sulfonamide
cyclopentanecarboxylic acid [4-(benzenesulfonyl)-2-tert-butyl-5-methyl-3-pyrazolyl] ester	[no description available]	low	0	0	sulfonamide
4-[[(4-acetamidophenyl)sulfonylamino]methyl]-N-(3-methoxypropyl)benzamide	[no description available]	low	0	0	sulfonamide
4-methyl-N-[2,4,6-trioxo-1-phenyl-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
6-ethyl-2-[[[4-(4-morpholinylsulfonyl)phenyl]-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide	[no description available]	low	0	0	sulfonamide
4-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide	[no description available]	low	0	0	benzenes; sulfonamide
4-[[(4-methylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide	[no description available]	low	0	0	sulfonamide
2-[(5-chloro-1,3-benzothiazol-2-yl)thio]-N-[3-(4-morpholinylsulfonyl)phenyl]propanamide	[no description available]	low	0	0	sulfonamide
N-(6-ethoxy-1,3-benzothiazol-2-yl)-4-methoxy-3-(4-morpholinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
2-ethoxy-3-pyridinecarboxylic acid [2-[2-methyl-5-(4-morpholinylsulfonyl)anilino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
N-[4-[2-(2-ethyl-1-oxobutyl)-3-phenyl-3,4-dihydropyrazol-5-yl]phenyl]methanesulfonamide	[no description available]	low	0	0	sulfonamide
N-[3-[(2-chlorophenyl)sulfamoyl]-4-methoxyphenyl]-4-oxo-4-thiophen-2-ylbutanamide	[no description available]	low	0	0	sulfonamide
2-(4-methyl-N-(4-methylphenyl)sulfonylanilino)-N-[(1-methyl-4-piperidinylidene)amino]acetamide	[no description available]	low	0	0	sulfonamide
fh535	[no description available]	low	0	0	sulfonamide
1-[4-chloro-3-[(2-methoxyphenyl)sulfamoyl]phenyl]-3-(2-methoxyphenyl)urea	[no description available]	low	0	0	sulfonamide
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-2-(2-pyrimidinylthio)acetamide	[no description available]	low	0	0	sulfonamide
2-[[[5-(dimethylsulfamoyl)-2-methylanilino]-sulfanylidenemethyl]hydrazo]-2-oxoacetamide	[no description available]	low	0	0	sulfonamide
1-(4-butylphenyl)-3-[4-chloro-3-(dimethylsulfamoyl)phenyl]thiourea	[no description available]	low	0	0	sulfonamide
6-methyl-2-[[oxo-[4-(1-pyrrolidinylsulfonyl)phenyl]methyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide	[no description available]	low	0	0	sulfonamide
2-(1,3-benzothiazol-2-ylthio)-N-[2-hydroxy-5-(4-morpholinylsulfonyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
1-butyl-4,6-dimethyl-3-(2-methylphenyl)sulfonyl-2-pyridinone	[no description available]	low	0	0	sulfonamide
4-(4-methylphenyl)sulfonyl-3-phenyl-2,3-dihydro-1,4-benzoxazine	[no description available]	low	0	0	sulfonamide
N-[3-(4-methyl-1-piperazinyl)-1,4-dioxo-2-naphthalenyl]benzenesulfonamide	[no description available]	low	0	0	1,4-naphthoquinones; piperazines; sulfonamide
N-(2,2,4-trimethyl-3H-benzofuran-7-yl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-furanyl-[4-(4-propan-2-ylphenyl)sulfonyl-1-piperazinyl]methanone	[no description available]	low	0	0	sulfonamide
5-amino-2-(diethylamino)-N-(2-methoxyphenyl)benzenesulfonamide	[no description available]	low	0	0	benzenes; sulfonamide
N-(1,3-dimethyl-2-oxo-5-benzimidazolyl)-4-fluoro-3-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-(diethylsulfamoyl)-2-methoxyphenyl]-2-[(2,5-dimethylphenyl)thio]acetamide	[no description available]	low	0	0	sulfonamide
2-[(5-anilino-1,3,4-thiadiazol-2-yl)thio]-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]-N-[3-(1-imidazolyl)propyl]benzamide	[no description available]	low	0	0	sulfonamide
2-[[3-(3-oxo-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid	[no description available]	low	0	0	sulfonamide
N-[(1,2-dimethyl-5-indolyl)methyl]-4-methoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N,6-dimethyl-2-[[[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]-oxomethyl]amino]-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide	[no description available]	low	0	0	sulfonamide
N-cyclopropyl-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[1-(1H-benzimidazol-2-yl)ethyl]-3-(dimethylsulfamoyl)benzamide	[no description available]	low	0	0	sulfonamide
N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-4-[(3-methyl-1-piperidinyl)sulfonyl]benzamide	[no description available]	low	0	0	sulfonamide
N-[4-[(1,2-dimethyl-5-indolyl)methylsulfamoyl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
2,3-dihydro-1,4-benzodioxin-3-carboxylic acid [2-[2-methyl-5-(4-morpholinylsulfonyl)anilino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
2-[[5-(4-methylanilino)-1,3,4-thiadiazol-2-yl]thio]-N-[3-(3,4,5,6-tetrahydro-2H-azepin-7-ylsulfamoyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
2-(1,3-benzothiazol-2-ylthio)-N-[2-chloro-5-(4-morpholinylsulfonyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
1-[3-(dimethylsulfamoyl)phenyl]-3-(2-furanylmethyl)thiourea	[no description available]	low	0	0	sulfonamide
5-nitro-2-furancarboxylic acid [2-oxo-2-[3-(1-piperidinylsulfonyl)anilino]ethyl] ester	[no description available]	low	0	0	sulfonamide
N-[2-(4-methoxyphenyl)ethyl]-2-nitro-4-(1-pyrrolidinylsulfonyl)aniline	[no description available]	low	0	0	benzenes; sulfonamide
N-(2-ethoxyphenyl)-2,1,3-benzothiadiazole-4-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[3-[2-(4-fluorophenyl)sulfonyl-3-thiophen-2-yl-3,4-dihydropyrazol-5-yl]phenyl]ethanesulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]-4-[(2-methyl-1-piperidinyl)sulfonyl]benzamide	[no description available]	low	0	0	sulfonamide
N-[(3,5-dimethyl-1-piperidinyl)-sulfanylidenemethyl]-2-methyl-5-(4-morpholinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
4-[bis(2-methoxyethyl)sulfamoyl]-N-[5-(methoxymethyl)-1,3,4-oxadiazol-2-yl]benzamide	[no description available]	low	0	0	sulfonamide
2-(benzenesulfonamido)-6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester	[no description available]	low	0	0	isopropyl ester; sulfonamide
2-(3,4-dichlorophenyl)-N-[3-(dimethylsulfamoyl)-4-methylphenyl]acetamide	[no description available]	low	0	0	sulfonamide
N-Cyclopentyl-2-(N-methyl3-chlorobenzenesulfonamido)acetamide	[no description available]	low	0	0	sulfonamide	anticoronaviral agent
N-[5-(1-azepanylsulfonyl)-2-chlorophenyl]-2-[(4-methyl-1,2,4-triazol-3-yl)thio]acetamide	[no description available]	low	0	0	sulfonamide
1-(4-methoxyphenyl)-3-[3-(1-piperidinylsulfonyl)phenyl]thiourea	[no description available]	low	0	0	sulfonamide
1-[2-(trifluoromethyl)phenyl]sulfonyl-4-piperidinecarboxylic acid [2-[(4-fluorophenyl)methylamino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid [2-[4-methyl-3-(1-piperidinylsulfonyl)anilino]-2-oxoethyl] ester	[no description available]	low	0	0	sulfonamide
3-[4-(4-butan-2-ylphenyl)sulfonyl-1-piperazinyl]butanoic acid	[no description available]	low	0	0	sulfonamide
3-[(2,6-dimethyl-4-morpholinyl)sulfonyl]-N-(5-methyl-2-thiazolyl)benzamide	[no description available]	low	0	0	sulfonamide
2-[[4-(2-methoxyphenyl)sulfonyl-1-piperazinyl]sulfonyl]benzonitrile	[no description available]	low	0	0	sulfonamide
2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-N-[3-(diethylsulfamoyl)phenyl]acetamide	[no description available]	low	0	0	sulfonamide
3-[(4-methyl-1-piperazinyl)sulfonyl]-N-(4-phenyl-2-thiazolyl)-N-prop-2-enylbenzamide	[no description available]	low	0	0	sulfonamide
1-(7-methyloctyl)-3-[4-(4-morpholinylsulfonyl)phenyl]thiourea	[no description available]	low	0	0	sulfonamide
5-[(5-bromo-2-ethoxyphenyl)sulfonylamino]-2-chloro-N,N-dimethylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[[5-[(4-fluorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]-N-(3-sulfamoylphenyl)acetamide	[no description available]	low	0	0	sulfonamide
N,N-dimethyl-3-(3-oxo-1,2-benzothiazol-2-yl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]-4-(1-pyrrolidinylsulfonyl)benzamide	[no description available]	low	0	0	sulfonamide
4-(dimethylsulfamoyl)-N-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]benzamide	[no description available]	low	0	0	sulfonamide
N-methyl-2-[[[4-[methyl(phenyl)sulfamoyl]phenyl]-oxomethyl]amino]-6-propyl-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxamide	[no description available]	low	0	0	sulfonamide
1-[4-chloro-3-(4-morpholinylsulfonyl)phenyl]-3-phenylurea	[no description available]	low	0	0	sulfonamide
3-(4-methylphenyl)sulfonyl-3-azabicyclo[2.2.1]hept-5-ene-2-carboxylic acid	[no description available]	low	0	0	sulfonamide
N-(3,4-difluorophenyl)-2-[N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-ethoxyanilino]acetamide	[no description available]	low	0	0	sulfonamide
5-[(4-methoxyphenyl)sulfonylmethyl]-N-(3-methoxypropyl)-2-furancarboxamide	[no description available]	low	0	0	sulfonamide
N-cyclohexyl-N-ethyl-1,3-dimethyl-2,4-dioxo-5-pyrimidinesulfonamide	[no description available]	low	0	0	pyrimidone; sulfonamide
1,3-dimethyl-2,4-dioxo-N-(4-propan-2-ylphenyl)-5-pyrimidinesulfonamide	[no description available]	low	0	0	sulfonamide
2,5-dimethoxy-N-[[2-(4-methoxyphenyl)-4-thiazolyl]methyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
kn 93	[no description available]	low	0	0	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
ro 4-6790	[no description available]	low	0	0	benzenes; sulfonamide
jnj-7706621	[no description available]	low	0	0	sulfonamide
sultan	[no description available]	low	0	0	sulfonamide
1-[2-furanyl(oxo)methyl]-N-[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-4-piperidinecarboxamide	[no description available]	low	0	0	sulfonamide
sb 269970	[no description available]	low	0	0	sulfonamide
belinostat	[no description available]	low	0	0	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
2-bromo-N-(phenylmethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-(2,5-dichlorophenyl)sulfonyl-N-methyl-N-[(2-methylphenyl)methyl]ethanamine	[no description available]	low	0	0	sulfonamide
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide)	[no description available]	low	0	0	sulfonamide
N-[2-methyl-5-(2-thiazolo[5,4-b]pyridinyl)phenyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[[4-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
5-chloro-N-[4-(2-thiazolo[5,4-b]pyridinyl)phenyl]-2-thiophenesulfonamide	[no description available]	low	0	0	sulfonamide
4-methyl-N-[[4-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide	[no description available]	low	0	0	organofluorine compound; pyrazoles; sulfonamide	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
bm 567	[no description available]	low	0	0	benzenes; sulfonamide
mre 269	[no description available]	low	0	0	aromatic amine; ether; monocarboxylic acid; pyrazines; sulfonamide; tertiary amino compound	drug metabolite; orphan drug; platelet aggregation inhibitor; prostacyclin receptor agonist; vasodilator agent
pazopanib	[no description available]	low	0	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
azd2858	[no description available]	low	0	0	aromatic amine; N-methylpiperazine; pyrazines; pyridines; secondary carboxamide; sulfonamide	antineoplastic agent; bone density conservation agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator
4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid	[no description available]	low	0	0	sulfonamide
apratastat	[no description available]	low	0	0	sulfonamide
N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide	[no description available]	low	0	0	sulfonamide
florasulam	[no description available]	low	0	0	sulfonamide
(1S,2R)-2-[[4-[(2,4-dimethylphenyl)sulfamoyl]anilino]-oxomethyl]-1-cyclohexanecarboxylic acid	[no description available]	low	0	0	sulfonamide
3-[1-(4-bromophenyl)sulfonyl-3,6-dihydro-2H-pyridin-4-yl]-1,2-dimethylindole	[no description available]	low	0	0	sulfonamide
4-[3-(3-fluorophenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
2-[[[4-[(2,6-dimethyl-4-morpholinyl)sulfonyl]phenyl]-oxomethyl]amino]-3-thiophenecarboxamide	[no description available]	low	0	0	sulfonamide
4-[3-(4-methylphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-[ethyl(phenyl)sulfamoyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide	[no description available]	low	0	0	sulfonamide
calcium crimson	[no description available]	low	0	0	ammonium betaine; sulfonamide	fluorochrome
4-methoxy-N-[[1-[(3-methyl-2-thiophenyl)-oxomethyl]-3-piperidinyl]methyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N'-[[3-(4-methylphenyl)sulfonyl-2-oxazolidinyl]methyl]-N-[2-(4-sulfamoylphenyl)ethyl]oxamide	[no description available]	low	0	0	sulfonamide
tg101209	[no description available]	low	0	0	N-alkylpiperazine; N-arylpiperazine; pyrimidines; secondary amino compound; sulfonamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
fedratinib	[no description available]	low	0	0	sulfonamide
WAY-316606	[no description available]	low	0	0	(trifluoromethyl)benzenes; piperidines; secondary amino compound; sulfonamide; sulfone	secreted frizzled-related protein 1 inhibitor
azd5438	[no description available]	low	0	0	sulfonamide
gdc 0941	[no description available]	low	0	0	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
4-methoxy-N-[[4-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-[methyl-(3-methylphenyl)sulfamoyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide	[no description available]	low	0	0	sulfonamide
gsk 1016790a	[no description available]	low	0	0	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist
plx 4720	[no description available]	low	0	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
gsk 2126458	[no description available]	low	0	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(4-fluorophenyl)sulfonylpiperazine	[no description available]	low	0	0	sulfonamide
(2R)-4-(2,6-difluorophenyl)sulfonyl-1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-2-methylpiperazine	[no description available]	low	0	0	sulfonamide
[4-(2,6-difluorophenyl)sulfonyl-1-piperazinyl]-(2,3-dihydro-1,4-benzodioxin-6-yl)methanone	[no description available]	low	0	0	sulfonamide
(2R)-1-(2,6-difluorophenyl)sulfonyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-2-methylpiperazine	[no description available]	low	0	0	sulfonamide
(2S)-4-(2,6-difluorophenyl)sulfonyl-1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-2-methylpiperazine	[no description available]	low	0	0	sulfonamide
(2S)-1-(2,6-difluorophenyl)sulfonyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-2-methylpiperazine	[no description available]	low	0	0	sulfonamide
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2-pyridinylsulfonyl)piperazine	[no description available]	low	0	0	pyridines; sulfonamide
N-[1-(2,6-difluorophenyl)sulfonyl-4-piperidinyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
1-(2,6-difluorophenyl)sulfonyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepane	[no description available]	low	0	0	sulfonamide
N-[4-[(2,6-difluorophenyl)sulfonylamino]cyclohexyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[3-(trifluoromethyl)phenyl]sulfonylpiperazine	[no description available]	low	0	0	sulfonamide
N-[[1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-3-azetidinyl]methyl]-2,6-difluorobenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[[1-(2,6-difluorophenyl)sulfonyl-3-azetidinyl]methyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-3-pyrrolidinyl]-2,6-difluorobenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[3-[(2,6-difluorophenyl)sulfonylamino]propyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[5-[(2,6-difluorophenyl)sulfonylamino]pentyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[6-[(2,6-difluorophenyl)sulfonylamino]hexyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[2-[(2,6-difluorophenyl)sulfonylamino]ethyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[1-(2,6-difluorophenyl)sulfonyl-3-pyrrolidinyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
N-[4-[(2,6-difluorophenyl)sulfonylamino]butyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2-nitrophenyl)sulfonylpiperazine	[no description available]	low	0	0	sulfonamide
4-[4-(4-methylphenyl)sulfonyl-1-piperazinyl]-2-thiophen-2-ylquinazoline	[no description available]	low	0	0	sulfonamide
plx4032	[no description available]	low	0	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
N-[[4-[(2,6-difluorophenyl)sulfonylamino]cyclohexyl]methyl]-2,3-dihydro-1,4-benzodioxin-6-sulfonamide	[no description available]	low	0	0	sulfonamide
1-(3-chlorophenyl)sulfonyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine	[no description available]	low	0	0	sulfonamide
1-(3-bromophenyl)sulfonyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine	[no description available]	low	0	0	sulfonamide
(1S,4S)-2-(2,6-difluorophenyl)sulfonyl-5-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-2,5-diazabicyclo[2.2.1]heptane	[no description available]	low	0	0	sulfonamide
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2,4,6-trifluorophenyl)sulfonylpiperazine	[no description available]	low	0	0	sulfonamide
N-(1-cyano-3-pyrrolidinyl)-3-methoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(1-cyano-3-pyrrolidinyl)-4-(trifluoromethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(1-cyano-4-piperidinyl)-4-(trifluoromethyl)benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-[3-(3-methylphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
4-[3-(3-bromophenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
1-cyclohexyl-3-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)sulfonyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]urea	[no description available]	low	0	0	sulfonamide
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-thiophenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[(2S,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]cyclopropanecarboxamide	[no description available]	low	0	0	sulfonamide
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]methanesulfonamide	[no description available]	low	0	0	sulfonamide
N-[[(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[(2R,3S)-2-[[(4-chlorophenyl)sulfonyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4,4,4-trifluorobutanamide	[no description available]	low	0	0	sulfonamide
3-cyclohexyl-1-[[(2S,3S)-8-[(4-fluorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	0	sulfonamide
3-cyclohexyl-1-[[(2R,3R)-10-[(4-fluorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea	[no description available]	low	0	0	sulfonamide
4-chloro-N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
1-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-[4-(trifluoromethyl)phenyl]urea	[no description available]	low	0	0	sulfonamide
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide	[no description available]	low	0	0	sulfonamide
4-fluoro-N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[(2R,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-(1-methyl-3-indolyl)acetamide	[no description available]	low	0	0	sulfonamide
1-[(2R,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-[4-(trifluoromethyl)phenyl]urea	[no description available]	low	0	0	sulfonamide
baricitinib	[no description available]	low	0	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine	[no description available]	low	0	0	sulfonamide
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine	[no description available]	low	0	0	sulfonamide
sr1001	[no description available]	low	0	0	sulfonamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-methoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
dabrafenib	[no description available]	low	0	0	1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide	anticoronaviral agent; antineoplastic agent; B-Raf inhibitor
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline	[no description available]	low	0	0	benzenes; sulfonamide
4-[[(4-ethylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide	[no description available]	low	0	0	sulfonamide
EG00229	[no description available]	low	0	0	benzothiadiazole; dicarboxylic acid monoamide; L-arginine derivative; secondary carboxamide; sulfonamide; thiophenes	angiogenesis inhibitor; antineoplastic agent; neuropilin receptor antagonist
gsk0660	[no description available]	low	0	0	sulfonamide
xl765	[no description available]	low	0	0	aromatic amine; aromatic ether; benzamides; quinoxaline derivative; sulfonamide	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)-oxomethyl]-1H-pyrrol-2-yl]methylidene]-N-methyl-2-oxo-1H-indole-5-sulfonamide	[no description available]	low	0	0	sulfonamide
tipranavir	[no description available]	low	0	0	sulfonamide	antiviral drug; HIV protease inhibitor
abt-333	[no description available]	low	0	0	aromatic ether; naphthalenes; pyrimidone; sulfonamide	antiviral drug; nonnucleoside hepatitis C virus polymerase inhibitor
pik 75	[no description available]	low	0	0	sulfonamide
vx-970	[no description available]	low	0	0	sulfonamide
pf-543	[no description available]	low	0	0	sulfonamide
ML355	[no description available]	low	0	0	benzothiazoles; monomethoxybenzene; phenols; secondary amino compound; substituted aniline; sulfonamide	EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; platelet aggregation inhibitor
sr9243	[no description available]	low	0	0	bromobenzenes; sulfonamide; sulfone	antineoplastic agent; apoptosis inducer; liver X receptor inverse agonist
sildenafil	[no description available]	low	0	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
da 8159	[no description available]	low	0	0	sulfonamide
3-[[2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]-2-oxoethyl]thio]-6-methyl-2H-1,2,4-triazin-5-one	[no description available]	low	0	0	sulfonamide
N-tert-butyl-3-(3-tert-butyl-1-methyl-7-oxo-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxybenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[4-[2-[3-(dimethylsulfamoyl)anilino]-6H-1,3,4-thiadiazin-5-yl]phenyl]acetamide	[no description available]	low	0	0	sulfonamide
N-[2-[(4-chlorophenyl)methylthio]-4-oxo-1H-pyrimidin-6-yl]benzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-[2-[(2-chlorophenyl)methylthio]-4-oxo-1H-pyrimidin-6-yl]-4-methylbenzenesulfonamide	[no description available]	low	0	0	sulfonamide
N-(4-methoxyphenyl)-2-[[6-[(4-methylphenyl)sulfonylamino]-4-oxo-1H-pyrimidin-2-yl]thio]acetamide	[no description available]	low	0	0	sulfonamide
mirodenafil	[no description available]	low	0	0	aromatic ether; N-alkylpiperazine; primary alcohol; pyrrolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
da-8164	[no description available]	low	0	0	sulfonamide

Condition	Relationship Strength	Studies	Trials
Airway Obstruction	medium	1	1
Allergic Contact Dermatitis	low	1	0
American Trypanosomiasis	low	1	0
Anoxemia	low	1	0
Anoxia	low	1	0
Blood Diseases	medium	1	1
Breast Cancer	low	1	0
Breast Carcinoma	low	1	0
Breast Neoplasms	low	1	0
Breast Tumors	low	1	0
Brucella Infection	low	1	0
Brucellosis	low	1	0
Brucellosis, Pulmonary	low	1	0
Cancer of Breast	low	1	0
Cancer of Liver	low	1	0
Cancer of Lung	medium	2	2
Cancer of Stomach	low	2	0
Cancer of the Breast	low	1	0
Cancer of the Liver	low	1	0
Cancer of the Lung	medium	2	2
Cancer of the Stomach	low	2	0
Cancer of the Tongue	low	1	0
Cancer of Tongue	low	1	0
Cancer, Hepatocellular	low	1	0
Carcinoma, Epidermoid	low	1	0
Carcinoma, Non-Small Cell Lung	medium	2	2
Carcinoma, Planocellular	low	1	0
Carcinoma, Squamous	low	1	0
Carcinoma, Squamous Cell	low	1	0
Chagas Disease	low	1	0
Chagas' Disease	low	1	0
Choking	medium	1	1
Cholera	low	1	0
Cronobacter Infections	low	1	0
Cyprus Fever	low	1	0
Deficiency, Oxygen	low	1	0
Dermatitis, Allergic Contact	low	1	0
Dermatitis, Allergic Eczematous	low	1	0
Dermatitis, Contact, Allergic	low	1	0
Dermatomycoses	low	1	0
Dermatomycosis	low	1	0
Dermatophyte Infection	low	1	0
Enterobacteriaceae Infections	low	1	0
Enterobacterial Infections	low	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer	low	1	0
ER-Negative PR-Negative HER2-Negative Breast Neoplasms	low	1	0
Experimental Hepatoma	low	1	0
Experimental Hepatomas	low	1	0
Experimental Liver Neoplasms	low	1	0
Fungal Skin Diseases	low	1	0
Gastric Cancer	low	2	0
Gastric Cancer, Familial Diffuse	low	2	0
Gastric Neoplasms	low	2	0
Gastric Ulcer	low	2	0
Gastritis	low	1	0
Gibraltar Fever	low	1	0
Glaucoma	low	1	0
Hematologic Diseases	medium	1	1
Hematological Diseases	medium	1	1
Hepatic Cancer	low	1	0
Hepatic Neoplasms	low	1	0
Hepatocellular Cancer	low	1	0
Hepatocellular Carcinoma	low	2	0
Hepatoma	low	2	0
Hepatoma, Experimental	low	1	0
Hepatoma, Morris	low	1	0
Hepatoma, Novikoff	low	1	0
Hepatomas, Experimental	low	1	0
Human Mammary Carcinoma	low	1	0
Hypoxemia	low	1	0
Hypoxia	low	1	0
Infections, Enterobacteriaceae	low	1	0
Infections, Enterobacterial	low	1	0
Infections, Salmonella	low	1	0
Inflammation	low	1	0
Innate Inflammatory Response	low	1	0
Leishmania Infection	low	1	0
Leishmaniasis	low	1	0
Liver Cancer	low	1	0
Liver Cancer, Adult	low	2	0
Liver Cell Carcinoma	low	2	0
Liver Cell Carcinoma, Adult	low	2	0
Liver Neoplasms	low	1	0
Liver Neoplasms, Experimental	low	1	0
Lung Cancer	medium	2	2
Lung Neoplasms	medium	2	2
Malignant Neoplasm of Breast	low	1	0
Malignant Tumor of Breast	low	1	0
Malta Fever	low	1	0
Mammary Cancer	low	1	0
Mammary Carcinoma, Human	low	1	0
Mammary Neoplasm, Human	low	1	0
Mammary Neoplasms, Human	low	1	0
Metastase	medium	1	1
Metastases, Neoplasm	medium	1	1
Metastasis	medium	1	1
Metastasis, Neoplasm	medium	1	1
Muscle Contraction	low	1	0
Necrosis	low	3	0
Neoplasm Metastases	medium	1	1
Neoplasm Metastasis	medium	1	1
Neoplasms, Breast	low	1	0
Neoplasms, Experimental Liver	low	1	0
Neoplasms, Gastric	low	2	0
Neoplasms, Hepatic	low	1	0
Neoplasms, Liver	low	1	0
Neoplasms, Lung	medium	2	2
Neoplasms, Pulmonary	medium	2	2
Neoplasms, Stomach	low	2	0
Neoplasms, Tongue	low	1	0
Non-Small Cell Lung Cancer	medium	2	2
Non-Small Cell Lung Carcinoma	medium	2	2
Non-Small-Cell Lung Carcinoma	medium	2	2
Nonsmall Cell Lung Cancer	medium	2	2
Oxygen Deficiency	low	1	0
Pulmonary Cancer	medium	2	2
Pulmonary Neoplasms	medium	2	2
Rock Fever	low	1	0
Salmonella Infections	low	1	0
Salmonellosis	low	1	0
Scalp Dermatoses	low	1	0
Scalp Dermatosis	low	1	0
Skin Diseases, Fungal	low	1	0
Squamous Cell Carcinoma	low	1	0
Stomach Cancer	low	2	0
Stomach Neoplasms	low	2	0
Stomach Ulcer	low	2	0
Tongue Cancer	low	1	0
Tongue Neoplasms	low	1	0
Triple Negative Breast Cancer	low	1	0
Triple Negative Breast Neoplasms	low	1	0
Triple-Negative Breast Cancer	low	1	0
Triple-Negative Breast Neoplasm	low	1	0
Trypanosoma cruzi Infection	low	1	0
Trypanosomiasis, South American	low	1	0
Tumors, Breast	low	1	0
Undulant Fever	low	1	0
Vibrio cholerae Infection	low	1	0

4-toluenesulfonamide

Description

Cross-References

Synonyms (105)

Drug Classes (1)

Protein Targets (40)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (19)

Molecular Functions (8)

Ceullar Components (15)

Bioassays (216)

Research

Studies (108)

Study Types

Research Highlights

Bioavailability (1)

Dosage (1)

Interactions (1)

Article	Year
Ligand binding efficiency: trends, physical basis, and implications. Journal of medicinal chemistry, Apr-24, Volume: 51, Issue: 8	2008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial. Lung cancer (Amsterdam, Netherlands), Volume: 98	2016
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
An evaluation of para toluene-sulfonamide metabolism and effect with regard to CYP isoforms, P-glycoprotein, and drug interactions. Die Pharmazie, Volume: 61, Issue: 10	2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

4-toluenesulfonamide

Description

Cross-References

Synonyms (105)

Drug Classes (1)

Protein Targets (40)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (19)

Molecular Functions (8)

Ceullar Components (15)

Bioassays (216)

Research

Studies (108)

Study Types

Related Drugs (986)

Related Conditions (140)

Research Highlights

Bioavailability (1)

Dosage (1)

Interactions (1)